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A helminth chitinase structurally similar to mammalian chitinase displays 60 
immunomodulatory properties 61 
 62 
Abstract 63 
Previously, we reported significant immunomodulatory effects of the entire excretory-secretory 64 
(ES) proteins of the first larval stage (L1) of the gastrointestinal nematode Trichuris suis in a 65 
rodent model of allergic hyperreactivity. In the present study, we aimed to identify the proteins 66 
accounting for the modulatory effects of the T. suis L1 ES proteins and thus studied selected 67 
components for their immunomodulatory efficacy in an OVA-induced allergic airway disease 68 
model. In particular, an enzymatically active T. suis chitinase mediated amelioration of airway 69 
hyperreactivity, primarily associated with suppression of eosinophil recruitment into the lung. 70 
The three-dimensional structure of the T. suis chitinase as determined by high-resolution X-ray 71 
crystallography revealed significant similarities to mouse acidic mammalian chitinase 72 
(AMCase). In addition, the unique ability of T. suis chitinase to form dimers, as well as acidic 73 
surface patches within the dimerization region may contribute to the formation of cross-reactive 74 
antibodies to the mouse homologs. This hypothesis is supported by the observation that T. suis 75 
chitinase treatment induced cross-reactive antibodies to mouse AMCase and chitinase-like 76 
protein BRP-39 in the AHR model. In conclusion, a biologically active T. suis chitinase exhibits 77 
immunomodulatory properties despite its structural similarity to the mammalian counterpart.  78 
 79 
Author summary (150-200, non-technical summary) 80 
Experimental immunotherapy via reintroduction of intestinal worms to treat and prevent 81 
autoimmune, chronic inflammatory or allergic diseases is being discussed but the underlying 82 
mechanisms are still not fully understood. Here, we investigated the immunomodulatory 83 
potential of specific proteins of the whipworm Trichuris suis that are secreted very early during 84 
larval development. Using a murine model of allergic lung disease, we show that in particular 85 
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one T. suis protein, functionally characterized as an active chitinase, is reducing the lung 86 
inflammation. The T. suis chitinases three-dimensional protein structure revealed remarkable 87 
similarities to the hosts’ chitinase, an enzyme known to play a pivotal role in lung allergy. We 88 
also show that treatment with the helminth chitinase induced cross-reactive antibody responses 89 
against murine chitinase and chitinase-like proteins, both being inflammatory marker and 90 
regulators of type 2 immunity. Thus, our study provides a novel mechanism of 91 
immunomodulation by helminth components and may contribute to a better understanding of 92 
clinical responses of patients receiving helminthic therapy. 93 
 94 
Keywords (different from title wording): excretory/secretory proteins, whipworm, anti-95 
inflammatory efficacy, allergic airway disease, protein dimerization, parasite-host interaction 96 
97 
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Introduction 98 
Chronic helminth infections are known to be accompanied by various immunomodulatory 99 
processes. The active modulation of host immune responses is believed to ensure long term 100 
persistence of the parasites and most likely involves proteins released by the worms (reviewed 101 
in (1–3)). Over the last decade, research has focused on identifying secreted helminth 102 
immunomodulators and mechanisms of suppression in order to understand natural infection and 103 
in parallel with the aim to exploit this knowledge for the benefit of unwanted human 104 
inflammatory diseases. 105 
We and others have identified secreted products with immunosuppressive effects in 106 
autoimmune and inflammatory diseases from diverse parasitic helminths such as 107 
Acanthocheilonema viteae (4–11), Schistosoma (12–15), Fasciola hepatica (16,17), 108 
Heligmosomoides polygyrus (18,19), and Wuchereria bancrofti (20,21). Among the organisms 109 
currently explored for helminth-induced therapy of humans are the pig whipworm (Trichuris 110 
suis, TSO), the human hookworm (Necator americanus, NC), and also the human whipworm 111 
(T. trichiura, TTO). As T. suis can be easily maintained in pigs, but cannot multiply in humans, 112 
its administration as live parasite (TSO therapy) has been tested in a variety of clinical studies 113 
to improve human immune disorders (reviewed in (22)). Early success stories of treatments of 114 
ulcerative colitis (UC) and Crohn’s disease (CD) with TSO (23–25) were followed by larger 115 
trials with only modest results for various autoimmune diseases (22,26–28) and implicated the 116 
need for a greater understanding for the immunomodulatory mechanisms. 117 
T. suis has a direct life cycle. Upon ingestion of larval stage 1 (L1) containing infective eggs, 118 
the larvae hatch and invade the mucosa of the large intestine and develop into adults by molting 119 
several times (29). When administered therapeutically to humans, there is evidence for a self-120 
limiting, sterile colonization of T. suis (23), thus repeated TSO treatments are required. 121 
However, this transient exposure highlights the role of early larval stages to possess 122 
immunomodulatory properties. Using soluble products (Ts-SPs), or excretory-secretory 123 
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proteins (Ts-ES) or isolated fractions from both adult worms and larval stages, several 124 
immunomodulatory mechanisms have been investigated (30–33). Ts-SPs from adult worms 125 
have been shown to interfere with activation of human dendritic cells and macrophages (31,34–126 
37). We have reported on the immunomodulatory capacities of Ts-ES proteins from freshly 127 
hatched T. suis L1 in vitro by interfering with CD4+ T cell priming and in vivo by reducing 128 
clinical disease in a model of allergic airway disease (33). A recent study profiled Ts-ES 129 
proteins released by adult and larval stages of T. suis, and proved adult and larval (28-day 130 
larvae) Ts-ES possess anti-inflammatory properties. Indeed, the authors identified a subset of 131 
proteins with anti-inflammatory functions within adult Ts-ES (30). However, 132 
immunoregulators of the very early larval stages, the L1 of T. suis remain elusive. 133 
Here, we concentrate on the identification and characterization of proteins selectively secreted 134 
by the first larval stages, the L1 of T. suis. We screened a set of recombinant larval proteins for 135 
immunomodulatory properties in a murine model of allergic airway disease and identified an 136 
enzymatically active T. suis chitinase that suppressed disease progression and recruitment of 137 
airway inflammatory cells. X-ray crystallography revealed the structure of the nematode 138 
enzyme to be highly similar to the host’s chitinases. Application of T. suis chitinase in the 139 
disease model induced cross-reactive antibodies to AMCase and chitinase-like protein BRP39. 140 
This implicated the contribution of T. suis chitinase, a structural similar enzyme to mammalian 141 
AMCase, in the immunomodulatory properties of secreted helminth proteins. 142 
 143 
Materials and Methods 144 
Animals 145 
Female BALB/c mice were purchased from Janvier Labs (Le Genest-Saint-Isle, France). Mice 146 
were maintained at the Institute of Immunology, Department of Veterinary Medicine in Berlin 147 
and cared for in accordance with the principles outlined in the European Convention for the 148 
Protection of Vertebrate Animals used for Experimental and other Scientific Purposes and the 149 
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German Animal Welfare Law. The mouse study was approved by the State Office of Health 150 
and Social Affairs Berlin, Germany (Landesamt für Gesundheit und Soziales; approval number 151 
G0144/10 and G0068/16). 152 
 153 
Murine OVA-induced allergic airway disease 154 
Allergic airway inflammation was induced as previously described (4). Briefly, female BALB/c 155 
mice (8 weeks old) were sensitized on days 0 and 14 with 20 µg ovalbumin protein (OVA, 156 
grade VI, Sigma-Aldrich Chemie GmbH, Munich, Germany) emulsified in 2 mg alum 157 
(Imject™ Alum, Thermo Fisher Scientific, IL, USA). Non-allergic control animals (PBS) 158 
received equal volumes of PBS on days 0 and 14 instead of OVA. Mice were treated with 20 µg 159 
recombinant, intact T. suis proteins or heat inactivated proteins on days 0, 7 and 14 i.p., or left 160 
untreated. Intranasal OVA challenge (50 µg OVA/25 µl PBS) was performed on all groups of 161 
mice on days 28 and 29. Where indicated, lung function was assessed on day 30 at the Max 162 
Delbrück Center for Molecular Medicine (MDC) in Berlin. On day 31, mice were sacrificed, 163 
bronchoalveolar lavage (BAL) was performed and samples were taken for analysis. 164 
 165 
Airway hyperreactivity 166 
Airway resistance and lung function was assessed via double chamber plethysmography (emka 167 
Technologies, Paris, France) in response to increasing doses of acetyl-ß-methylcholine 168 
(Metacholine, Sigma-Aldrich Chemie GmbH, Munich, Germany). 169 
Mice were placed into a restrainer without anesthesia, adjusted (5 min) and the following 170 
protocol was applied: baseline measurement (4min), PBS (1 min), measurement (4 min), 171 
6.25 mg/ml methacholine (1 min), measurement (4 min), 12.5 mg/ml methacholine (1 min), 172 
measurement (4 min), 25 mg/ml (1 min) methacholine, measurement (4min), 50 mg/ml 173 
methacholine (1 min), measurement (4 min).  174 
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Data were sampled once per second. For data analysis, averages of 5 sec intervals were used. 175 
Airway resistance (Sraw) and expiratory time values were generated and analyzed using iox2 176 
Software (iox v2.8.0.13, EMKA Technologies). Resulting data points were averaged again per 177 
mouse and methacholine dose. Data points with success rate < 50% and beat number <10 were 178 
excluded from the analysis. 179 
 180 
Bronchoalveolar lavage 181 
Intratracheal bronchoalveolar lavage (BAL) was performed on i.p. anaesthetized mice by 182 
inflating the lungs with 800 µl PBS containing protease inhibitor cocktail (cOmplete™, Mini, 183 
EDTA-free Protease Inhibitor, Roche Diagnostics GmbH, Mannheim, Germany). The 1st BAL 184 
was pelleted and the supernatant was stored at -20°C for cytokine/chemokine detection. Four 185 
additional lavages (4× 800 µl PBS) were performed for cell isolation and pelleted by 186 
centrifugation. All cells were pooled in 500 µl PBS and counted using a Neubauer cell chamber. 187 
2× 100 µl cell suspension per sample were used for cytospin preparation. Object slides were 188 
dried and stained with Diff-Quick solutions (Labor und Technik Eberhard Lehmann GmbH, 189 
Berlin, Germany) for differential cell counts. Residual cells were used for flow cytometry. 190 
 191 
Histology and immunohistochemistry 192 
Following lung lavage, the left lobe was split into two pieces. The lower tissue was degassed 193 
and fixed in a formalin solution (Roti-Histofix 10%, Carl Roth GmbH + Co. KG, Karlsruhe, 194 
Germany) for 6 h at room temperature and then stored at 4 °C. The tissue was embedded in 195 
paraffin and sections were stained with an antibody against RELM-α (polyclonal rabbit anti-196 
mouse, Abcam, Cambridge, UK). Nuclei were stained with haematoxylin (Merck). Interstitial 197 
RELM-α+ cells were quantified in 5 HPF (high power fields, 400x magnification). Pictures are 198 
presented at 400x magnification. For evaluation of histomorphological changes, paraffin 199 
sections were stained with hematoxylin and eosin (H&E) and scored for inflammation and 200 
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goblet cell hyperplasia. Briefly, score 1 for minor perivascular inflammation, score 2 for 201 
moderate perivascular and peribronchial inflammation and minimal goblet cell hyperplasia, 202 
score 3 for increased perivascular and peribronchial inflammation and increased goblet cell 203 
hyperplasia (beginning in smaller airways) and score 4 for severe perivascular, peribronchial 204 
and interstitial inflammation with goblet cell hyperplasia in smaller and larger airways. 205 
 206 
Multiplex assay 207 
Bronchoalveolar lavage supernatants were analyzed for cytokine and chemokine levels using 208 
the Mouse Cytokine & Chemokine 26-plex ProcartaPlexTM Panel (ThermoFisher, MA, USA) 209 
according to the manufacturer’s instructions. The MAGPIXTM instrument (Luminex) was used 210 
and data were analyzed with Procarta PlexTM Analyst 1.0. 211 
 212 
Flow cytometry 213 
The following monoclonal fluorochrome conjugated anti-mouse antibodies were used: 214 
CD11b (clone M1/70, APC-Cy7), CD64 (clone X54-5/7.1, PE-Cy7), IgG1 (clone RMG1-1, 215 
APC), IgG2a (clone RMG2a-62, PerCP-Cy5.5) were purchased from BioLegend, CA, USA. 216 
CD45 (clone 30-F11, eF450), MHC-II (clone M5/114.15.2, PE-Cy5), Gr1 (clone RB6-8C5, 217 
PE-Cy7), EpCAM (clone G8.8, APC) were purchased from eBioscience, CA, USA. CD11c 218 
(clone HL3, FITC), MHC-II (clone M5/114.15.2, PE), SiglecF (clone E50-2440, PE) were 219 
purchased from BD Biosciences, CA, USA. Viability dye in eFluor 506, eF660, eF780 and 220 
Streptavidin (FITC) were purchased from eBioscience, CA, USA. Polyclonal biotynilated anti-221 
mouse Relm-α was purchased from Peprotech, NJ, USA. Samples were acquired using Canto 222 
II (BD Biosciences, CA, USA) and analyzed using Flow Jo software v9, Tristar. 223 
 224 
Quantitative RT-PCR 225 
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Following lung lavage, the upper right lobe was snap-frozen in liquid nitrogen and stored at -226 
80 °C. RNA-Isolation from lung tissues was performed using the innuPREP RNA Mini Kit 227 
(Analytic Jena AG, Jena, Germany) according to manufacturer’s instructions. Reverse 228 
transcription of 1 µg RNA into cDNA was done using the High-Capacity cDNA Reverse 229 
Transcription Kit (Applied Biosystems, CA, USA). RT-PCR was performed on the 230 
LightCycler® 480 instrument using the LightCycler® 480 SYBR Green I Master mix (Roche 231 
Diagnostics, Mannheim, Germany) and oligonucleotides listed in Table 1. Gene expression is 232 
described relative to the housekeeping gene peptidylprolyl isomerase A (PPIA) and normalized 233 
to mRNA levels of the PBS group if not indicated differently. 234 
 235 
Table 1. Sequences of oligonucleotides 236 
Gene Fwd primer (5’-3’) Rev primer (5’-3’) 
Chia1 
(AMCase) 
CCCTTGGCATATCCACTGA ACAGAATCCACTGCCTCCAG 
Ccl11 
(Eotaxin1) 
CTGCTTGATTCCTTCTCTTTCCTAA GGAACTACATGAAGCCAAGTCCTT 
Ccl2 
(MCP-1) 
TTAAAAACCTGGATCGGAACCAA GCATTAGCTTCAGATTTACGGGT 
Arg1 
(Arginase) 
CAGAAGAATGGAAGAGTCAG CAGATATGCAGGGAGTCACC 
Housekeeping- 
gene PPIA 
GAGCTGTTTGCAGACAAAGTTC CCCTGGCACATGAATCCTGG 
 237 
Isolation of T. suis larvae and production of excretory-secretory (ES) proteins 238 
The T. suis life cycle was maintained in pigs (Sus scrofa) and the generation of larval material 239 
approved by the State Office of Health and Social Affairs Berlin, Germany (Landesamt für 240 
Gesundheit und Soziales; approval number H0296/12). Pigs were orally infected with 8000 241 
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embryonated T. suis eggs in 2 ml NaCl (0.9%). Following euthanasia on days 10, 18, 28 dpi 242 
T. suis larvae were manually collected from the caecum and colon. Larvae were washed 4 times 243 
for 15 min each in RPMI-1640 (PAN-Biotech, Aidenbach, Germany) supplemented with 200 244 
U/ml penicillin, 200 µg/ml Streptomycin, 1.35 µg/ml Amphotericin B (all purchased from 245 
PAN-Biotech) by sedimentation and incubated overnight in RPMI-1640 supplemented with 1% 246 
Glucose (Sigma-Aldrich, St. Louis, US), 100 U/ml Penicillin, 100 µg/ml Streptomycin and 247 
0.625 µg/ml Amphotericin B. Culture medium was replaced and larvae were incubated for 248 
another 5 days while conditioned media was collected every 2nd day, sterilized by filtration 249 
(0.45 µm Minisart Syringe Filter, Sartorius AG, Göttingen, Germany) and stored at -20 °C. 250 
T. suis L1 ES proteins were isolated from freshly hatched larvae as previously described (33). 251 
Identification of T. suis larvae ES proteins (in vitro hatched L1, 10 dpi, 18 dpi, 28 dpi) was done 252 
by mass spectrometry as previously described (33). In brief, TCA-precipitated dried protein 253 
pellets of T. suis were suspended, reduced, alkylated and tryptic digested. The resulting peptides 254 
were analyzed by LC-MSMS on a 4700 proteomics Analyzer (ABSCIEX, Framingham, MS). 255 
Database searches were performed with Mascot software against NCBI database 20150331 256 
(64057457 sequences). Proteins were accepted as identified if at least two MS/MS spectra 257 
provided a MASCOT score for identity (p<0.01). 258 
 259 
Recombinant protein expression 260 
T. suis mRNA was isolated out of 10-20 mg worms by using the innuPREP RNA Mini Kit 261 
(Analytic Jena AG, Jena, Germany) according to manufacturer’s instructions. Reverse 262 
transcription of 1 µg RNA into cDNA was done using the Transcriptor First Strand cDNA 263 
Synthesis Kit (Roche Diagnostics GmbH, Mannheim, Germany).  264 
The genes corresponding to selected T. suis proteins were amplified and cloned into the vector 265 
pLEXSYsat2 of the Leishmania Expression System (LEXSYcon2 Expression Kit, Jena 266 
Bioscience GmbH, Jena, Germany). The cloning vector was sequenced for verification. 267 
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Leishmania tarentolae cells were transfected via electroporation (NucleofectorTM 2b Device, 268 
AmaxaTM Human T Cell NucleofectorTM Kit, Lonza, Basel, Switzerland) with the respective 269 
expression cassette containing the selective antibiotic marker Nourseothricin (NTC) and the 270 
T. suis protein coding gene. Transfected L. tarentolae cells were polyclonally selected and 271 
maintained as described in the manual. 272 
 273 
Protein purification 274 
His6-tag fused, recombinant proteins secreted by transfected Leishmania cells were purified by 275 
liquid chromatography over His-TrapTM excel columns (GE Healthcare, Buckinghamshire, 276 
United Kingdom). Protein-containing fractions were pooled and dialysed two times against 277 
PBS (4 h and overnight). Finally, protein concentrations were assessed using PierceTM BCA 278 
Protein Assay Kit (ThermoFisher Scientific, Rockford, USA). Identity of purified, recombinant 279 
proteins was verified by LC-MSMS analysis after tryptic digestion. 280 
 281 
SDS-PAGE and Western Blot 282 
To validate recombinant expression of T. suis proteins, a 12% SDS gel was loaded with 1-2 µg 283 
purified, recombinant T. suis proteins and developed using silver staining (Pierce SilverStain 284 
kit, ThermoFisher Scientific, Rockford, US). 285 
To visualize recombinant murine chitinases and CLPs, a 12% SDS gel was loaded with 20 µl 286 
cell culture supernatant of transfected COS-cells, 0.25 µg recombinant T. suis chitinase and 287 
0.2 µg p53. Proteins were transferred to a nitrocellulose membrane (Amersham Protran 0.45 288 
µm NC, GE Healthcare, Buckinghamshire, UK) using a semi-dry Western Blot system. 289 
Membranes were blocked for 1 h at room temperature in blocking buffer (5% BSA, PBS, 0.1% 290 
Tween). For detection of recombinant mouse chitinases, CLPs, p53 and Ts-Chit, an anti-His6-291 
Tag antibody (1:200, Dianova GmbH, Hamburg, Germany) was used and, where indicated, 292 
pooled mouse serum (from n = 4 animals) at a 1:100 dilution in blocking buffer, followed by 293 
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washing (PBS, 0.1% Tween) and incubation with goat anti-mouse IgG-HRP (1:2500) for 1 h at 294 
room temperature. After washing, blots were developed using WesternBright ECL (advansta, 295 
CA, USA) according to the manufacturer’s instructions and images were recorded with the 296 
chemiluminescence system Fusion SL 3500 WL (peqlab - VWR, Erlangen, Germany). 297 
 298 
Chitinase assay 299 
Chitinase activity was analyzed by using the substrate and standard solutions of the fluorimetric 300 
chitinase assay kit (Sigma-Aldrich Chemie GmbH, Munich, Germany). Substrates 4-MU-301 
(GlcNAc)2 (Exo-Chitinase activity) and 4-MU-(GlcNAc)3 (Endo-Chitinase activity) were 302 
adjusted to 1100 µM in DMSO and diluted 1:20 in assay buffer (100 mM citric acid, 200 mM 303 
sodium phosphate, pH 5.6) immediately prior to starting the assay by adding 50 µl of diluted 304 
substrate solution to 10 µl of protein KFD48490.1 (Ts_Chit) (5 µg/ml). The reaction mix was 305 
incubated for 30 min at 37 °C, and then quenched by adding 500 µl stop solution (500 mM 306 
sodium carbonate, 500 mM sodium bicarbonate, pH 10.7). 250 µl of the reaction solution were 307 
transferred in duplicates into a black 96-well plate and fluorescence of liberated 4-MU was 308 
measured using an excitation wavelength of 360 nm and recording emission at 450 nm. The 309 
effect of pH on KFD48490.1/Ts_Chit chitinase activity was determined by using assay buffers 310 
adjusted to pH = 2, 3, 4, 5, 6, 7, 8, 9 and 10. Heat stability of Ts_Chit chitinase was assessed by 311 
pre-incubation of the protein for 60 min at different temperatures (4°C – 90°C) followed by the 312 
chitinase assay. 313 
 314 
Crystallization and X-ray data collection 315 
The recombinant protein solution was dialyzed after initial purification in 20mM HEPES buffer 316 
(pH 7.5) and purified over a HiLoad 16/600 Superdex 200 pg column with a HEPES running 317 
buffer (20 mM HEPES pH 7.7, 200 mM NaCl, 1 mM TCEP). Elution fractions were 318 
concentrated using Amicon Ultra-4 concentrator tubes (30,000 MWKO) to a final concentration 319 
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of 33 mg/ml. A Gryphon pipetting robot was used to set up crystallization plates using the 320 
JSCG-plus Screen by mixing 0.25 µl protein solution with 0.25 µl crystallization cocktail 321 
solution. Plates were sealed and incubated at 20°C. Crystal growth was monitored regularly 322 
under an optical microscope. The crystals appeared in condition H7 (0.8 M ammonium sulfate, 323 
0.1 M BIS-Tris pH 5.5, 25% (w/v) PEG 3350). Protein crystals were harvested, cryo-protected 324 
using reservoir solution supplemented with 25% (v/v) ethylene glycol and stored in liquid 325 
nitrogen. Diffraction data were collected on BL14.1 at the BESSY II synchrotron of the 326 
Helmholtz-Zentrum Berlin (38) and processed using XDSAPP (39). Relevant processing 327 
statistics are shown in Table 2. The structure was solved by molecular replacement using the 328 
structure of Human Chitotriosidase (CHIT1) as a search model (PDB-Id 5HBF, (40)). After 329 
several cycles of manual rebuilding using COOT (41) and refinement using REFMAC5 (42), 330 
refinement converged at R-factors of 19 and 23 % for the working R and the free R, respectively 331 
(Table 3). The refined structure features good refinement statistics and excellent geometric 332 
parameters. The refined coordinates and the associated structure factor amplitudes were 333 
deposited in the PDB using the accession code 6G9C. 334 
 335 
Structure based sequence alignment and surface electrostatics. 336 
To obtain an overview of structural similarities and differences between Ts-Chit and host 337 
chitinases, the topology and secondary structure elements of Ts-Chit were compared to six 338 
mouse chitinases and chitinase-like proteins by means of a structure-based amino acid sequence 339 
alignment (see Supplementary Information S2). Secondary structure elements were predicted 340 
with PSIPRED (43) and a structure-based amino acid sequence alignment was constructed 341 
using SBAL (44). 342 
In order to assess whether Ts-Chit possesses any features that might serve as a potential 343 
molecular mimicry of host chitinases when acting as an antigen, we undertook a comparison of 344 
surface features of Ts-Chit with mouse chitinases. In general, this approach is limited by the 345 
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availability of only one experimental 3D structure of mouse chitinases. Using the amino acid 346 
sequences of three mouse chitinases (M. musculus AMCase, Chit1 isoform 1 and Ym1), known 347 
3D structures or close structural homologues of these proteins were identified in the PDB using 348 
pGenThreader (45), revealing mouse AMCase as the only mouse protein suitable for 349 
comparison in this context. 350 
Using the monomer and dimer structures of Ts-Chit as well as the structure of mouse AMCase 351 
(PDB 3FY1), surface electrostatics for these three proteins were calculated with APBS (46), 352 
and visualized with UCSF Chimera (47). 353 
 354 
Statistical analysis 355 
Statistical analysis was done using GraphPad Prism software v7 (GraphPad Software, Ca, USA) 356 
using Kruskal-Wallis test (Dunn’s multiple comparisons test), Mann-Whitney test or unpaired 357 
Student’s t-test as indicated. Values with p < 0.05 (*), p < 0.005 (**), p < 0.001 (***) were 358 
considered to be significant. 359 
 360 
 361 
Results 362 
T. suis L1 stage-specific excretory-secretory protein KFD48490.1 affects allergic airway 363 
inflammation 364 
We previously showed that T. suis excretory/secretory proteins (ES proteins) collected from L1 365 
hatched in vitro reduced clinical signs of murine allergic airway disease (33). To identify the 366 
early released immunomodulatory proteins responsible for this effect, we now investigated the 367 
protein composition of L1 ES proteins and compared it to L2, L3 and L4 larval stages of T. suis 368 
released products. For stage-specific expression patterns, parasites were isolated from pigs 369 
infected with 8000 TSO at 10, 18 and 28 days post-infection (resulting in L2, L3, and L4 larvae, 370 
respectively) and cultivated to collect conditioned media for mass spectrometry. Alternatively, 371 
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eggs were hatched in vitro to generate L1 larvae and conditioned media, as previously described 372 
(33). Comparative proteomic analysis of T. suis ES proteins (Fig. 1A and Supplementary 373 
Table S1) revealed some overlap between first stage (in vitro hatched) L1 larvae and L2 larvae 374 
(10 day larvae), but no overlap of L1 ES proteins with later stages of larval development (L3 375 
ES - 18 day larvae and L4 ES - 28 day larvae). Four L1-specific proteins and two L1/L2-specific 376 
proteins with predicted signal sequences and a lack of transmembrane domains (Table 2) were 377 
recombinantly expressed. Since glycosylation can be crucial for the immunomodulatory effects 378 
of secreted helminth proteins, we used the eukaryotic expression system LEXSY, based on the 379 
protozoan L. tarentolae (Fig. 1B). Notably, selected T. suis L1 proteins were distinct in size 380 
(ranging from 13 to 56 kDa, Fig. 1C), predicted glycosylation sites and homology-based 381 
annotation (Table 2). 382 
We initially screened for immunomodulatory effects of the six recombinant T. suis L1 proteins 383 
using the OVA (ovalbumin)-induced allergic airway hyperreactivity model in female BALB/c 384 
mice. Mice were treated with recombinant T. suis proteins during sensitization with the allergen 385 
OVA on days 0, 7 and 14 (Fig. 1D). The numbers of total BAL infiltrates and BAL eosinophils 386 
were detected 2 days after the 2nd intranasal OVA challenge at day 31 (Fig. 1D) and analyzed 387 
in parallel to control mice lacking OVA sensitization, but receiving OVA-challenge (PBS) and 388 
untreated allergic mice (OVA). Analysis of total cell numbers and cellular composition of the 389 
BAL fluid found that KFD48490.1 (homologous to T. trichiura acidic mammalian chitinase) 390 
and KFD45500.1 (homologous to T. trichiura venom allergen 5) reduced the total numbers of 391 
cellular BAL fluid infiltrates, but only KFD48490.1 treated mice showed a significant reduction 392 
of eosinophils infiltrating the lungs in comparison to untreated allergic (OVA) mice (Fig. 1 E 393 
and F). 394 
 395 
Table 2. MALDI-TOF MS verified T. suis L1 ES proteins that were selected and recombinantly 396 
expressed using LEXSY 397 
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NCBI-ID 
MW        
(kDa) 
Known homology 
 
N- 
Glycosylation 
O- 
Glycosylation 
KFD48490.1 55.45 Acidic mammalian chitinase  
[T. trichiura] - 28 
KFD55729.1 13.89 - 
 - 1 
KFD54802.1 31.06 CAP domain containing protein 
[T. trichiura] 3 10 
KFD45500.1 37.04 venom allergen 5 
[T. trichiura] 1 24 
KFD47618.1 14.18 hypothetical protein 
[T. trichiura] - - 
 KFD53667.1* 31.06 hypothetical protein 
[T. trichiura] 5 - 
Sequence similarity search for protein homology was performed using BLAST/NCBI. Glycosylation prediction was performed 398 
using NetOGlyc 4.0.0.13 for O-Glycosylation and NetNGlyc 1.0 Server for N-Glycosylation. * formerly identified using HelmDB 399 
database and recombinantly expressed based on this sequence. 400 
 401 
Immunoregulatory KFD48490.1 is an active chitinase of T. suis L1 larvae 402 
Based on amino acid sequence similarity, database research predicted KFD48490.1 was 403 
homologous to acidic mammalian chitinase (AMCase) of T. trichiura (Table 2). The amino 404 
acid sequence of KFD48490.1 revealed the presence of the catalytic motive DxDxE (T. suis 405 
DLDWE, Fig. 2A), typically observed for active chitinases, and a C-terminal chitin-binding 406 
domain with cysteine residues responsible for the chitin binding (Fig. 2A). Alignment studies 407 
additionally proved high sequence similarities to other known helminth chitinases including a 408 
putative endochitinase from the pig infecting Ascaris suum and a glycosyl hydrolase from the 409 
human hookworm N. americanus (Fig. 2B). Active chitinases cleave chitin from the end of a 410 
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polymer chain (exochitinase) and/or hydrolyse small oligomers to generate N-411 
acetylglucosamine monomers within the oligomer chain (endochitinase) (48). To examine 412 
whether KFD48490.1 exerts true chitinase activity, we used two different substrates, 4-MU-413 
(GlcNAc)3 and 4-MU-(GlcNAc)2, allowing us to evaluate both endo- and exochitinase activity, 414 
respectively (Fig. 2C). KFD48490.1 clearly presented both, endo- and exochitinase activity, 415 
whereas extensive, heat-induced proteolysis resulted in a loss of chitinase activity (Fig. 2C). 416 
With regard to the biology of nematodes, we explored the influence of low pH and high 417 
temperatures hypothesizing that T. suis chitinase will be active at low pH and elevated 418 
temperatures in the pig’s intestine to support larval hatching and development (49,50). 419 
Interestingly, KFD48490.1 remained enzymatically active over a wide range of pH 4–7 (Fig. 420 
2D) and up to temperatures of 50°C (Fig. 2E). Together, these data confirmed the functional 421 
annotation of KFD48490.1 as T. suis L1 true chitinase, and thus the protein is referred to as Ts-422 
Chit from hereon. 423 
 424 
T. suis chitinase (Ts-Chit)-mediated regulation of airway hyperreactivity only partially 425 
depends on protein integrity 426 
To describe the effects of Ts-Chit treatment on allergic airway disease we analyzed airway 427 
resistance, expiration time and BAL fluid profiles in more detail. In addition, we included a 428 
group of mice treated with heat-inactivated, recombinant Ts-Chit to assess whether 429 
immunomodulatory effects were linked to the enzymatically active T. suis chitinase protein.  430 
Treatment of animals with intact and active Ts-Chit significantly reduced the number of total 431 
cells (Fig. 3A) and eosinophils (Fig. 3B) present in BAL fluid 2 days after 2nd OVA-challenge. 432 
Differential cell counts of BAL fluid further revealed that neutrophil numbers were largely 433 
unaffected (Fig. 3C). A trend towards an increase of alveolar macrophages cell numbers was 434 
observed in Ts-Chit compared to allergic (OVA) mice (Fig. 3D). Flow cytometry of BAL cells 435 
confirmed the reduced frequency of eosinophils (CD45+CD11b+GR1lowCD11c-SiglecF+) in Ts-436 
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Chit treated compared to untreated (OVA) allergic animals (Fig. 3E and F), and also supported 437 
increased frequencies of alveolar macrophages, identified as CD11blowCD11c+ cells among 438 
CD45+ cells (Fig. 3G), as observed as a trend in differential cell counts. The respiratory 439 
responses resulting from Ts-Chit treatment were measured using non-invasive whole-body 440 
plethysmography 24 h after OVA challenge. Importantly, also the non-sensitized control group 441 
(PBS) was intranasally challenged with OVA. Preventative administration of Ts-Chit caused 442 
restoration of expiration time to the level of PBS control mice at baseline (Fig. 3H). A trend in 443 
recovery was also noticed for treating with heat-inactivated Ts-Chit (Fig. 3H). Measuring 444 
airway resistance to increasing doses of methacholine (MCh) revealed that Ts-Chit treatment 445 
attenuated exacerbation of MCh-induced airway hyperreactivity), but treatment with 446 
inactivated Ts-Chit also had some effects (Fig. 3H, I and J). We next evaluated, whether the 447 
reduced cellularity and improved lung function observed in Ts-Chit treated animals was 448 
reflected in BAL cytokine levels. OVA sensitization and challenge caused a significant increase 449 
of the cytokines IL-4, IL-5 and IL-13 detected in BAL fluid; however, Ts-Chit treatment did 450 
not reduce but rather enhanced local Th2 cytokine production (Fig. 3K). Interestingly, Ts-Chit 451 
and heat-inactivated Ts-Chit alike accelerated IL-18 levels in BAL fluid (Fig. 3K), a cytokine 452 
known to induce IL-4, IL-5 and IL-13 release by mast cells and basophils (51). Thus, cellular 453 
infiltration and the respiratory response were improved in mice treated with Ts-Chit, but the 454 
Th2 cytokine response was unchanged or elevated in comparison to untreated allergic mice 455 
(OVA). 456 
To further delineate the direct effects of Ts-Chit treatment on lung inflammation of OVA-457 
sensitized and challenged mice, we investigated lung tissue pathology and recruitment of 458 
alternatively activated macrophages (AAM). While histopathological findings remained overall 459 
similar in the lungs of untreated (OVA) and Ts-Chit treated allergic animals (Fig. 4A), 460 
immunohistochemistry revealed increased numbers of interstitial RELMα + cells, a signature 461 
marker for AAM that mediates lung vascularization and tissue repair (52,53) when mice were 462 
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treated with Ts-Chit compared to OVA (Fig. 4B and C). A similar trend was observed for 463 
inactivated Ts-Chit treated animals. Since this was in contrast to our previous observation on 464 
Ts-ES L1-induced suppression of RELMα+ cells (33) and given that the resistin-like molecule 465 
(RELM) a is not only expressed in macrophages but also epithelial cells and tissue infiltrating 466 
eosinophils, we used smaller groups of mice to define Relma expression to a interstitial 467 
macrophage phenotype by flow cytometry. Lung tissue macrophages were analyzed in 468 
homogenates of lavaged lungs and defined as EpCAM-CD11c+CD64+MHCII+SiglecF- (Fig. 469 
4D). While overall frequencies of tissue macrophages were not affected by Ts-Chit treatment 470 
(Fig. 4E), we again detected an increase in Relma+ macrophages, but did not reach statistical 471 
significance (Fig. 4F). Contrary to the increase of Relma+ cells, RT-PCR of homogenized lung 472 
tissue of all groups of mice revealed downregulation of arginase-1 and MCP-1 mRNA when 473 
mice were treated with intact and also inactivated Ts-Chit compared to PBS (Fig. 4G). 474 
Supporting reduced numbers of eosinophil infiltration upon Ts-Chit treatment, we detected 475 
downregulation of CCL11/eotaxin mRNA, a potent eosinophil chemoattractant that stimulates 476 
recruitment of eosinophils from the blood to sites of allergic inflammation (Fig. 4E). Together, 477 
these data illustrate that protein integrity of the Ts-Chit is only partially responsible for the 478 
treatment effects leading to attenuated airway hyperreactivity. 479 
 480 
T. suis chitinase reveals high structural similarity to murine chitinase but presents dimeric 481 
structure 482 
Given the results of the in vivo AHR experiments with heat-inactivated Ts-Chit, a direct 483 
immunomodulatory effect of Ts-Chit or a role for its chitinase activity was very unlikely. Direct 484 
immunomodulatory effects of ES or soluble proteins from adult and larval parasitic nematodes 485 
have previously been shown in vitro and various modulatory activities were found such as 486 
targeting pro-inflammatory cytokine release from bone-marrow derived dendritic cells or 487 
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macrophages and induction of arginase-1, IL-10 and NO in macrophages (4,30,35,54,55), the 488 
suppression of antigen-specific or unspecific CD4+ T cell proliferation (56) or induction of 489 
Foxp3+ regulatory T cells (19,57). In contrast, recombinant T. suis chitinase failed to show 490 
strong immunomodulation in any of the above mentioned assays (data not shown). 491 
We therefore examined the implications of Ts-Chit treatment on the family of murine chitinases 492 
and chitinase-like proteins (CLP), that are highly implicated in pathology of Th2-mediated 493 
allergic airway inflammation (58). Interestingly, T. suis chitinase was shown to have a high 494 
percentage of amino acid sequence identity when compared to the two true murine chitinases 495 
(AMCase (41.6%) and Chit1(41.5%)) or the murine CLPs Ym1 (39%), Ym2 (37.5%) or BRP-496 
39 (36.7%) (Suppl. Fig. 2). 497 
To better understand structural differences between nematode and mammalian chitinases and 498 
the structural basis of the serological response to Ts-Chit treatment, we determined the crystal 499 
structure of the nematode chitinase protein by X-ray crystallography. The final model analysis 500 
data collection and refinement statistics are summarized in Table 3. They indicate that the 501 
structure is of high resolution, that it is well refined to very good statistics and hence that it is 502 
of high quality. The overall structure reveals a TIM-barrel or (ßa)8-barrel motif, which means 503 
that 8 ß-strands form the central barrel which is surrounded by 8 a-helices (Fig. 5A and C). 504 
The active site with the sequence motif D149xD151xE153 is depicted in Figure 5A.2. The crystal 505 
structure furthermore revealed a P2-symmetric dimer of the protein, which is stabilized by an 506 
intermolecular disulfide bond formed by a cysteine residue at position 180 (Fig. 5A.1 and B). 507 
Such dimerization has not been described so far for human or murine chitinases, nor has the 508 
occurrence of a cysteine residue at position 180. In addition, the structural alignment with 509 
human AMCase (3FXY), human chitotriosidase (1GUV), human YKL-40 (1NWR) and murine 510 
Ym1 (1VF8) (Fig. 5C) indicates highly similar structural features in the core regions (marked 511 
in red) and certain areas, mostly at the protein surface, where the structure differs between 512 
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nematode and mammalian chitinases (highlighted in green/blue). A detailed structure based 513 
sequence alignment of T. suis chitinase, mouse chitinases and CLPs is given in Supplementary 514 
S2. Notably, the C-terminal region of Ts-Chit from amino acid 401 to 495 contains many 515 
threonine repeats and is referred to as unordered region. The T. suis chitinase dimerization was 516 
further examined by comparing reducing (+ ß-mercaptoethanol) and non-reducing (- ß-517 
mercaptoethanol) conditions for SDS/PAGE loading. We indeed detected a second, higher band 518 
at around 75 kDa indicative for dimerization under non-reducing conditions (Fig. 5D). 519 
The structural und functional similarity of T. suis chitinase and murine AMCase could either 520 
mean that Ts-Chit is sensed similar to murine AMCase resulting in cumulative effects, or in 521 
turn, that Ts-Chit interferes with murine AMCase function. Following the idea that T. suis 522 
interferes with murine chitinase activity during allergic airway hyperreactivity, we more 523 
specifically compared surface features of Ts-Chit and mouse AMCase (PDB: 3FY1), the only 524 
acidic mouse chitinase with known experimental 3D structure. To that effect, the surface 525 
electrostatics for mammalian AMCase and the Ts-Chit monomer were visualized and appraised. 526 
While investigating the monomer alone did not reveal any strikingly identical surface patches, 527 
looking at the dimerization region around α3/α4-α3’/α4’ (α3:~127-142; α4:~161-180) revealed 528 
similarities with an acidic surface patch of AMCase (Fig. 6A). 529 
In summary, this first crystallographic structure analysis of a parasitic nematode chitinase 530 
revealed Ts-Chit dimerization and the concomitant existence of surface patches absent in the 531 
monomeric protein. The surface electrostatics of these dimer-specific patches show a 532 
remarkable similarity between T. suis chitinase and murine AMCase. 533 
 534 
 535 
Table 3. X-ray-based structure analysis data collection and refinement statistics. 536 
Crystallographic data Ts_Chit 
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Space group C2 
Cell parameters 
a, b, c (Å) 196, 52.6, 93.5 α, 
β, γ (°) 90, 108.8, 90 
Wavelength (Å) 0.91841 
Resolution (Å) 47.9-1.65 
Total reflections 609875 
Unique reflections 209810 
Completeness (%) 98.3 (97.4) 
CC1/2  0.99 (0.32) 
I/σ (I) 7.42 (0.31) 
Refinement statistics  
No. of reflections used 209322 
No. of reflections in test set 2200 
R factor 0.191 
Rfree 0.226 
RMS deviation  
Bonds (Å) 0.007 
Angles (°) 0.863 
Mean B factor (Å2) 44.11 
Ramachandran plot  
Residues in most favored regions 98.91 
Residues in additional allowed regions       1.09 
 537 
 538 
 539 
T. suis chitinase interferes with murine chitinase in AHR 540 
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Considering the structural similarities, we asked whether Ts-Chit treatment of allergic mice 541 
interfered with the effector functions of its murine counterpart, AMCase. And indeed, chitinase 542 
activity was found to be reduced in the BAL fluid of allergic mice treated with intact and 543 
inactivated Ts-Chit compared to untreated (OVA) mice (Fig. 7A). Similarly, we detected 544 
decreased AMCase transcript levels (Chia1) mRNA transcripts in lung tissues of allergic Ts-545 
Chit treated compared untreated (OVA) mice (Fig. 7B). 546 
Since chitinase inhibition by either administration of anti-AMCase sera (63), RNA interference 547 
(64) or small molecule inhibitors e.g. allosamidin (63,65) results in suppression of airway 548 
inflammation and hyperresponsiveness, we studied the serological response of cross-reactive 549 
anti-AMCase and anti-CLP antibodies. We speculated that the high degree of structural 550 
similarity between T. suis chitinase and murine chitinases or CLPs probably contributes to the 551 
development of cross-reactive antibodies when applied during allergic sensitization in murine 552 
AHR. 553 
Blotting recombinantly expressed murine AMCase and the CLPs Ym1, Ym2 and BRP-39 and 554 
probing the blots with AHR sera of Ts-Chit treated, allergic mice clearly demonstrated the 555 
presence of antibodies recognizing Ts-Chit but also murine AMCase and BRP-39 proteins (Fig. 556 
7C). In turn, the serum of untreated, allergic mice recognized OVA protein only, but no 557 
chitinases or CLPs (Fig. 7C). Together, these data indicate a functional role for cross-reactive 558 
antibodies to murine AMCase and BRP-39 that are induced by Ts-Chit treatment. 559 
 560 
Discussion 561 
Parasitic nematodes use a range of different mechanisms to not only invade their hosts, but also 562 
promote survival, growth and reproduction. A very elegant strategy involves 563 
immunomodulation of the host comprising of suppression, regulation or modulation of the host 564 
immune response. Being equipped with excretory and secretory systems (66), parasitic 565 
nematodes release numerous possible mediators into their environment that are most likely 566 
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involved in communicating with the host and shaping its immune response (1). It is those yet 567 
unidentified ES immunomodulatory molecules that bear the therapeutic potential for targeting 568 
immune-mediated diseases.  569 
The life cycle of many parasitic nematodes, however, is complex and involves uptake of 570 
infective larvae, hatching, host invasion or migration, growth and maturation, several molting 571 
events, mating and sexual reproduction. Accordingly, there is evidence for life cycle stage 572 
specific expression and release of distinct sets of ES molecules needed to fulfill those specific 573 
tasks (30,67,68). We have previously reported that total ES proteins of the very early larval 574 
stage (L1) of the whipworm T. suis very efficiently ameliorate allergic lung disease in a model 575 
of OVA-induced AHR when applied during the sensitization phase (33). Notably, in TSO 576 
therapy, patients are repeatedly exposed to the early larval stages of T. suis owing to the fact 577 
that T. suis only transiently infects human intestines (23,69). 578 
This led us to suggest a role for mediators being released very early during infection by the first 579 
larval stages. In this study, we therefore focused on the identification of specific L1 ES 580 
immunomodulators of T. suis and their immunomodulatory mechanisms. We compared ES 581 
proteins collected from hatched L1 versus later larval stages (10, 18 and 28 day old) isolated 582 
from the intestines of infected pigs by using LC-MS/MS. Among the 33 proteins that were 583 
identified in the ES of in vitro hatched T. suis L1, 8 proteins were also found in the ES of L2 584 
larvae, but no overlap to later larval stages. We concentrated on proteins selectively expressed 585 
by the first two larval stages (L1 and L2) and chose targets based on the presence of a signal 586 
peptide and the absence of a transmembrane domain. However, we recognize that a surprisingly 587 
large proportion of T. suis ES proteins are not encoded with a signal peptide, comparable with 588 
reports from other species (70–72). Over the course of this study, the genome of the porcine 589 
whipworm T. suis published in 2014 (73) had been complemented with two slightly larger 590 
assemblies of male and female worms, that in turn added on to the number of identified protein 591 
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IDs when reanalyzing our MS data. Hence, ongoing data base curation of the T. suis genome 592 
can increase the number of potential immunomodulatory proteins in ES products. 593 
Screening six recombinantly expressed L1 ES proteins, eukaryotically-produced in 594 
L. tarentolae, in a model of OVA-induced allergic airway hyperreactivity revealed that the 595 
application of T. suis KFD48490.1 markedly reduced inflammatory lung infiltrates, partly 596 
mimicking the effects of total T. suis L1 ES (33). Our results further proved that KFD48490.1 597 
is an enzymatically active chitinase of T. suis. The enzyme retained its high activity in the pH 598 
range from 4 to 6, and thus is relatively resistant to acidic pH similar to acidic mammalian 599 
chitinases of humans and mice (74,75).  600 
Chitinases are glycosyl hydrolases (GH) with the ability to directly degrade chitin polymers to 601 
low molecular weight chitooligomers (reviewed in (76)). Based on amino acid sequence 602 
similarity, the T. suis chitinase belongs to GH family 18 characterized by an enzyme core of 8 603 
b-strands forming a barrel that is surrounded by a-helices, as well as the conserved sequence 604 
DxDxE forming the active site. Chitinases have essential roles in the life cycle of many 605 
parasites, supported by the existence of multiple genes as well as tissue and stage-specific 606 
expression patterns (77–79). Chitinase activity in helminth biology is thought to be essential 607 
during embryonic development, larval molting and degradation of the chitinous matrix (80,81), 608 
suggesting that chitinases might be attractive intervention targets. RNAi experiments 609 
demonstrated that inhibition of helminth chitinase prevented larval molting and hatching of 610 
microfilaria, but also induced the death of female worms of the rodent filarial nematode 611 
Acanthocheilonema viteae (49). 612 
In the context of allergic lung disease, however, observing an active chitinase to mediate 613 
suppression of AHR was rather surprising. In recent years, studies in patients and animal models 614 
have shown that mammalian chitinases play a key role in mediating the Th2 driven 615 
inflammatory responses commonly associated with asthma and have been investigated to 616 
indicate disease severity (63,82,83). Mice express two enzymatically active chitinases, acidic 617 
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mammalian chitinase (AMCase) and chitotriosidase (Chit) and a set of enzymatically inactive 618 
chitinase-like proteins (Ym1, Ym2, BRP39). AMCase is secreted by macrophages and 619 
epithelial cells of lung and gut. In the lungs, it is constitutively expressed and secreted into the 620 
airway lumen. STAT6-activating signals, such as IL-13, further induce AMCase expression and 621 
elevated AMCase mRNA and protein levels are detected in BAL of OVA-induced asthmatic 622 
mice (63). This latter study also showed that administration of anti-AMCase sera reduced BAL 623 
and tissue eosinophilia and BAL chitinase activity. Similarly, in a gut inflammation model it 624 
has been shown that the pan-chitinase inhibitor caffeine was able to dampen inflammation in a 625 
DSS-induced colitis model (84). 626 
Here, we demonstrated that treating mice with a chitinase of T. suis (Ts-Chit) during 627 
sensitization reduced BAL eosinophilia, increased numbers of Relma+ interstitial cells, 628 
improved lung function and reduced chitinase activity in BAL. Interestingly, heat-inactivated 629 
Ts-Chit was able to partly phenocopy these effects in vivo. We have no evidence for active Ts-630 
Chit to induce Foxp3+ Treg cells, to interfere with antigen-specific and -unspecific T cell 631 
proliferation, to alter co-stimulatory molecule expression of antigen-presenting cells or induce 632 
NO in macrophages as shown in other studies (30,57). Yet, we cannot rule out any direct 633 
cellular effects of Ts-Chit on mammalian cells. Our in vivo results, however, suggest a 634 
mechanism related to the anti-AMCase-sera treatment of OVA-induced allergic mice reported 635 
by Zhu and colleagues (63). Similar to that study, we show here that Ts-Chit treatment had no 636 
suppressive effects on Th2 inductive responses such IL-4, IL-13 as well as IL-5 levels in BAL. 637 
Zhu and coworkers further demonstrated that anti-AMCase sera diminished the ability of IL-638 
13 to stimulate eotaxin and monocyte-chemotactic protein 1 (MCP-1), an effect that was 639 
induced by the worm chitinase in the present study. Besides anti-AMCase treatment, other 640 
approaches have been used to address AMCase activity, such as inhibition with small molecule 641 
(65) or RNA interference (64), and demonstrated suppressed eotaxin, MCP-1 and MIP-1ß 642 
levels when AMCase activity or expression was inhibited.  643 
.CC-BY 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/641837doi: bioRxiv preprint first posted online May. 17, 2019; 
29 
 
The underlying mechanisms on the ability of AMCase to promote chemokine and cytokine 644 
expression have been investigated by Hartl and coworkers (85) who showed that AMCase 645 
physically interacts with epidermal growth factor receptor (EGFR) to induce the production of 646 
e.g. MCP-1, CCL17, and IL-8 in lung epithelial cells. The authors also reported an autocrine 647 
and/or paracrine feedback mechanism for AMCase in protecting airway epithelial cells from 648 
Fas ligand (FasL)- and growth factor withdrawal-induced apoptosis (85,86). 649 
Sequence alignment demonstrates a relatively high degree of similarity between T. suis 650 
chitinase and AMCase, but also to CLPs such as YM1, Ym2 or BRP39. Given this homology 651 
of T. suis and murine chitinases and our in vivo observations on reduced chemokine expression 652 
and eosinophil infiltration, but non-suppressed Th2 responses, it is tempting to speculate that 653 
Ts-Chit administration during the sensitization phase induces cross-reactive antibodies that 654 
inhibit murine chitinases and/or CLPs. Ts-Chit treatment clearly induced an antibody response 655 
against murine AMCase and BRP-39 in our model of OVA-induced allergic asthma; 656 
additionally, we observed decreased chitinase activity in BAL and lung tissue decrease in 657 
AMCase transcripts. Whether decreased chitinase activity and reduced AMCase transcription 658 
are a consequence of the overall reduced lung inflammation or result from chitinase protein 659 
interference still need to be verified. 660 
The X-ray crystal structure of Ts-Chit reported here confirmed the expected high similarity of 661 
the nematode chitinase with murine acidic mammalian chitinase. In addition, analysis of surface 662 
electrostatics of the Ts-Chit dimer suggests the existence of an acidic surface patch on the 663 
nematode protein that bears similarity to a surface feature on AMCase monomers. This suggests 664 
that the response elicited by Ts-Chit may be due to molecular mimicry; however, future studies 665 
need to establish whether this is indeed the case. Site-directed mutagenesis within the 666 
dimerization region or the acidic surface patch will be needed to address the impact those 667 
structural features to the formation of cross-reactive antibodies. 668 
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Molecular mimicry is a phenomenon that is triggered by a high degree of similarity of pathogen 669 
and host epitopes and has previously been described for helminth defense molecules of Fasciola 670 
hepatica that mimic the molecular function of host antimicrobial molecules (87) or the TGF-ß 671 
mimic secreted by Heligmosomoides polygyrus with profound Treg-inducing capacities (19). 672 
To the best of our knowledge, a pathogen-driven molecular mimicry inducing antibodies that 673 
interfere with Th2-dependent host chitinase activity has not been described so far. 674 
 675 
An interesting thought that arises when considering the induction of cross-reactive antibodies 676 
under inflammatory conditions, is the heterologous response of patients receiving TSO therapy 677 
in published reports of multiple sclerosis (MS) or UC trials (28,88). Considering that a certain 678 
threshold of inflammation is required to trigger polyclonal B cell responses and induction of 679 
cross-reactive antibodies, it is conceivable that, depending on the individual inflammation score 680 
and its kinetics, TSO induces a more or less anti-inflammatory treatment response. 681 
In summary, our study investigated L1 stage-specific, secreted proteins of T. suis and their 682 
capacity for immunomodulation in treating allergic lung disease. We identified an active 683 
chitinase of T. suis that, when applied during sensitization of an allergic response, reduced 684 
eosinophilia and lung chemokine responses. These findings add to our understanding of specific 685 
functions of early secreted T. suis products in helminth biology and when considered as 686 
therapeutics to create an anti-inflammatory environment. The structural similarity between the 687 
worm chitinase and its host equivalent, the absence of direct cellular effects and the presence 688 
of cross-reactive antibodies potentially interfering with murine chitinase activity suggests an 689 
alternative mechanism of Ts-Chit ameliorating OVA-induced, allergic lung disease that likely 690 
involves structural mimicry. Such a mechanism of immunomodulation could be one of those 691 
unrecognized strategies of mediating anti-inflammatory responses that explain the degree of 692 
variation among the responses of individual TSO-treated subjects in clinical trials.  693 
 694 
.CC-BY 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/641837doi: bioRxiv preprint first posted online May. 17, 2019; 
31 
 
Acknowledgements 695 
The authors gratefully thank Marion Müller, Christiane Palissa, Yvonne Weber, Bettina 696 
Sonnenburg und Beate Anders for excellent technical assistance and Franziska Rohr for her 697 
help within the animal facility. We also thank Prof. Judith E. Allen for her expertise, critical 698 
advice and intellectual discussion of the topic. This work was supported by the German 699 
Research Foundation (GRK 1673 to S. H.), the FAZIT-STIFTUNG (to K. B.) and Coronado 700 
Biosciences (to S. H.). 701 
 702 
Author contribution (CRediT taxonomy) 703 
Conceptualization, F. E. and S. H.; Methodology, K. B., F. E., M. S. W., P. H. M., J. Z., K. J.; 704 
Investigation, K. B., F. E., A. A. K., K. J., A.N., M. S. W., P. H. M., A. H.; Data Curation, K. 705 
J., A. N., P. H. M.; Writing, F. E., K. B. and S. H.; Funding Acquisition, S. H.; Resources, T. 706 
E. S., A. H., M. S. W., J. Z., S. H.; Formal Analysis, A. H., A. A. K., A. H.; Visualization, F. 707 
E., K. B., P. H. M., M. S. W., A. H., Supervision, F. E., M. S. W. and S. H. 708 
 709 
References 710 
1.  Hewitson JP, Grainger JR, Maizels RM. Helminth immunoregulation: The role of 711 
parasite secreted proteins in modulating host immunity. Mol Biochem Parasitol. 2009 712 
Sep;167(1–9):1–11.  713 
2.  McSorley HJ, Hewitson JP, Maizels RM. Immunomodulation by helminth parasites: 714 
Defining mechanisms and mediators. International Journal for Parasitology. 2013 Mar 715 
1;43(3):301–10.  716 
3.  Coakley G, Buck AH, Maizels RM. Host parasite communications—Messages from 717 
helminths for the immune system. Mol Biochem Parasitol. 2016 Jul;208(1):33–40.  718 
.CC-BY 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/641837doi: bioRxiv preprint first posted online May. 17, 2019; 
32 
 
4.  Schnoeller C, Rausch S, Pillai S, Avagyan A, Wittig BM, Loddenkemper C, et al. A 719 
Helminth Immunomodulator Reduces Allergic and Inflammatory Responses by Induction of 720 
IL-10-Producing Macrophages. J Immunol. 2008 Mar 15;180(6):4265–72.  721 
5.  Daniłowicz-Luebert E, Steinfelder S, Kühl AA, Drozdenko G, Lucius R, Worm M, et 722 
al. A nematode immunomodulator suppresses grass pollen-specific allergic responses by 723 
controlling excessive Th2 inflammation. Int J Parasitol. 2013 Mar;43(3–4):201–10.  724 
6.  Whelan RA, Rausch S, Ebner F, Günzel D, Richter JF, Hering NA, et al. A Transgenic 725 
Probiotic Secreting a Parasite Immunomodulator for Site-Directed Treatment of Gut 726 
Inflammation. Molecular Therapy. 2014 Jul 2;  727 
7.  Ziegler T, Rausch S, Steinfelder S, Klotz C, Hepworth MR, Kühl AA, et al. A novel 728 
regulatory macrophage induced by a helminth molecule instructs IL-10 in CD4+ T cells and 729 
protects against mucosal inflammation. J Immunol. 2015 Feb 15;194(4):1555–64.  730 
8.  Pineda MA, Lumb F, Harnett MM, Harnett W. ES-62, a therapeutic anti-inflammatory 731 
agent evolved by the filarial nematode Acanthocheilonema viteae. Mol Biochem Parasitol. 732 
2014 Apr;194(1–2):1–8.  733 
9.  Rodgers DT, McGrath MA, Pineda MA, Al-Riyami L, Rzepecka J, Lumb F, et al. The 734 
Parasitic Worm Product ES-62 Targets Myeloid Differentiation Factor 88–Dependent Effector 735 
Mechanisms to Suppress Antinuclear Antibody Production and Proteinuria in MRL/lpr Mice. 736 
Arthritis Rheumatol. 2015 Apr;67(4):1023–35.  737 
10.  McInnes IB, Leung BP, Harnett M, Gracie JA, Liew FY, Harnett W. A Novel 738 
Therapeutic Approach Targeting Articular Inflammation Using the Filarial Nematode-Derived 739 
Phosphorylcholine-Containing Glycoprotein ES-62. The Journal of Immunology. 2003 Aug 740 
15;171(4):2127–33.  741 
11.  Rzepecka J, Siebeke I, Coltherd JC, Kean DE, Steiger CN, Al-Riyami L, et al. The 742 
helminth product, ES-62, protects against airway inflammation by resetting the Th cell 743 
phenotype. Int J Parasitol. 2013 Mar;43(3–4):211–23.  744 
.CC-BY 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/641837doi: bioRxiv preprint first posted online May. 17, 2019; 
33 
 
12.  Zaccone P, Fehérvári Z, Jones FM, Sidobre S, Kronenberg M, Dunne DW, et al. 745 
Schistosoma mansoni antigens modulate the activity of the innate immune response and prevent 746 
onset of type 1 diabetes. Eur J Immunol. 2003 May;33(5):1439–49.  747 
13.  Zaccone P, Burton O, Miller N, Jones FM, Dunne DW, Cooke A. Schistosoma mansoni 748 
egg antigens induce Treg that participate in diabetes prevention in NOD mice. European Journal 749 
of Immunology. 2009 Apr 1;39(4):1098–107.  750 
14.  Janssen L, Silva Santos GL, Muller HS, Vieira ARA, de Campos TA, de Paulo Martins 751 
V. Schistosome-Derived Molecules as Modulating Actors of the Immune System and 752 
Promising Candidates to Treat Autoimmune and Inflammatory Diseases. J Immunol Res. 2016 753 
;2016. 754 
15.  Sarazin A, Dendooven A, Delbeke M, Gatault S, Pagny A, Standaert A, et al. Treatment 755 
with P28GST, a schistosome-derived enzyme, after acute colitis induction in mice: Decrease of 756 
intestinal inflammation associated with a down regulation of Th1/Th17 responses. PLoS One. 757 
2018 Dec 28;13(12).  758 
16.  Ramos-Benitez MJ, Ruiz-Jimenez C, Rosado-Franco JJ, Ramos-Pérez WD, Mendez 759 
LB, Osuna A, et al. Fh15 Blocks the Lipopolysaccharide-Induced Cytokine Storm While 760 
Modulating Peritoneal Macrophage Migration and CD38 Expression within Spleen 761 
Macrophages in a Mouse Model of Septic Shock. mSphere. 2018 Dec 19;3(6).  762 
17.  Roig J, Saiz ML, Galiano A, Trelis M, Cantalapiedra F, Monteagudo C, et al. 763 
Extracellular Vesicles From the Helminth Fasciola hepatica Prevent DSS-Induced Acute 764 
Ulcerative Colitis in a T-Lymphocyte Independent Mode. Front Microbiol. 2018 May 23;9. 18. 765 
 McSorley HJ, Blair NF, Smith KA, McKenzie ANJ, Maizels RM. Blockade of IL-33 766 
release and suppression of type 2 innate lymphoid cell responses by helminth secreted products 767 
in airway allergy. Mucosal Immunol. 2014 Feb 5;  768 
.CC-BY 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/641837doi: bioRxiv preprint first posted online May. 17, 2019; 
34 
 
19.  Johnston CJC, Smyth DJ, Kodali RB, White MPJ, Harcus Y, Filbey KJ, et al. A 769 
structurally distinct TGF-β mimic from an intestinal helminth parasite potently induces 770 
regulatory T cells. Nat Commun. 2017 Nov 23;8.  771 
20.  Togre NS, Bhoj PS, Khatri VK, Tarnekar A, Goswami K, Shende MR, et al. SXP-RAL 772 
Family Filarial Protein, rWbL2, Prevents Development of DSS-Induced Acute Ulcerative 773 
Colitis. Indian J Clin Biochem. 2018 Jul;33(3):282–9.  774 
21.  Amdare NP, Khatri VK, Yadav RSP, Tarnekar A, Goswami K, Reddy MVR. 775 
Therapeutic potential of the immunomodulatory proteins Wuchereria bancrofti L2 and Brugia 776 
malayi abundant larval transcript 2 against streptozotocin-induced type 1 diabetes in mice. 777 
Journal of Helminthology. 2017 Sep;91(5):539–48.  778 
22.  Fleming JO, Weinstock JV. Clinical trials of helminth therapy in autoimmune diseases: 779 
rationale and findings. Parasite Immunology. 2015;37(6):277–92.  780 
23.  Summers RW, Elliott DE, Qadir K, Urban JF Jr, Thompson R, Weinstock JV. Trichuris 781 
suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease. 782 
Am J Gastroenterol. 2003 Sep;98(9):2034–41.  783 
24.  Summers RW, Elliott DE, Urban JF, Thompson RA, Weinstock JV. Trichuris suis 784 
therapy for active ulcerative colitis: A randomized controlled trial. Gastroenterology. 2005 Apr 785 
1;128(4):825–32.  786 
25.  Summers RW, Elliott DE, Urban JF, Thompson R, Weinstock JV. Trichuris suis therapy 787 
in Crohn’s disease. Gut. 2005 Jan 1;54(1):87–90.  788 
26.  Schölmerich J, Fellermann K, Seibold FW, Rogler G, Langhorst J, Howaldt S, et al. A 789 
Randomised, Double-blind, Placebo-controlled Trial of Trichuris suis ova in Active Crohn’s 790 
Disease. J Crohns Colitis. 2017 Apr;11(4):390–9.  791 
27.  Hollander E, Uzunova G, Taylor BP, Noone R, Racine E, Doernberg E, et al. 792 
Randomized crossover feasibility trial of helminthic Trichuris suis ova versus placebo for 793 
.CC-BY 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/641837doi: bioRxiv preprint first posted online May. 17, 2019; 
35 
 
repetitive behaviors in adult autism spectrum disorder. The World Journal of Biological 794 
Psychiatry. 2018 Sep 19;0(0):1–9.  795 
28.  Fleming J, Hernandez G, Hartman L, Maksimovic J, Nace S, Lawler B, et al. Safety and 796 
efficacy of helminth treatment in relapsing-remitting multiple sclerosis: Results of the HINT 2 797 
clinical trial. Mult Scler. 2019 Jan 1;25(1):81–91.  798 
29.  Beer RJS. Studies on the biology of the life-cycle of Trichuris suis Schrank, 1788. 799 
Parasitology. 1973 Dec;67(3):253–62.  800 
30.  Leroux L-P, Nasr M, Valanparambil R, Tam M, Rosa BA, Siciliani E, et al. Analysis of 801 
the Trichuris suis excretory/secretory proteins as a function of life cycle stage and their 802 
immunomodulatory properties. Scientific Reports. 2018 Oct 29;8(1):15921.  803 
31.  Kuijk LM, Klaver EJ, Kooij G, van der Pol SMA, Heijnen P, Bruijns SCM, et al. Soluble 804 
helminth products suppress clinical signs in murine experimental autoimmune 805 
encephalomyelitis and differentially modulate human dendritic cell activation. Molecular 806 
Immunology. 2012 Jun;51(2):210–8.  807 
32.  Hansen TVA, Williams AR, Denwood M, Nejsum P, Thamsborg SM, Friis C. Pathway 808 
of oxfendazole from the host into the worm: Trichuris suis in pigs. International Journal for 809 
Parasitology: Drugs and Drug Resistance. 2017 Dec 1;7(3):416–24.  810 
33.  Ebner F, Hepworth MR, Rausch S, Janek K, Niewienda A, Kühl A, et al. Therapeutic 811 
potential of larval excretory/secretory proteins of the pig whipworm Trichuris suis in allergic 812 
disease. Allergy. 2014 Jul 29;  813 
34.  Klaver EJ, Kuijk LM, Laan LC, Kringel H, van Vliet SJ, Bouma G, et al. Trichuris suis-814 
induced modulation of human dendritic cell function is glycan-mediated. International Journal 815 
for Parasitology. 2013 Mar;43(3–4):191–200.  816 
35.  Ottow MK, Klaver EJ, van der Pouw Kraan TCTM, Heijnen PD, Laan LC, Kringel H, 817 
et al. The helminth Trichuris suis suppresses TLR4-induced inflammatory responses in human 818 
macrophages. Genes Immun. 2014 Oct;15(7):477–86.  819 
.CC-BY 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/641837doi: bioRxiv preprint first posted online May. 17, 2019; 
36 
 
36.  Hoeksema MA, Laan LC, Postma JJ, Cummings RD, de Winther MPJ, Dijkstra CD, et 820 
al. Treatment with Trichuris suis soluble products during monocyte-to-macrophage 821 
differentiation reduces inflammatory responses through epigenetic remodeling. FASEB J. 822 
2016;30(8):2826–36.  823 
37.  Laan LC, Williams AR, Stavenhagen K, Giera M, Kooij G, Vlasakov I, et al. The 824 
whipworm (Trichuris suis) secretes prostaglandin E2 to suppress proinflammatory properties 825 
in human dendritic cells. FASEB J. 2017 Feb;31(2):719–31.  826 
38.  Mueller U, Förster R, Hellmig M, Huschmann FU, Kastner A, Malecki P, et al. The 827 
macromolecular crystallography beamlines at BESSY II of the Helmholtz-Zentrum Berlin: 828 
Current status and perspectives. Eur Phys J  Plus. 2015 Jul 22;130(7):141.  829 
39.  Sparta KM, Krug M, Heinemann U, Mueller U, Weiss MS. XDSAPP2.0. J Appl Cryst. 830 
2016 Jun 1;49(3):1085–92.  831 
40.  Fadel F, Zhao Y, Cousido-Siah A, Ruiz FX, Mitschler A, Podjarny A. X-Ray Crystal 832 
Structure of the Full Length Human Chitotriosidase (CHIT1) Reveals Features of Its Chitin 833 
Binding Domain. PLoS One. 2016 Apr 25;11(4).  834 
41.  Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta 835 
Crystallogr D Biol Crystallogr. 2010 Apr 1;66(Pt 4):486–501.  836 
42.  Murshudov GN, Vagin AA, Dodson EJ. Refinement of Macromolecular Structures by 837 
the Maximum-Likelihood Method. Acta Cryst D. 1997 May 1;53(3):240–55.  838 
43.  Bryson K, McGuffin LJ, Marsden RL, Ward JJ, Sodhi JS, Jones DT. Protein structure 839 
prediction servers at University College London. Nucleic Acids Res. 2005 Jul 1;33(Web Server 840 
issue):W36–8.  841 
44.  Wang CK, Broder U, Weeratunga SK, Gasser RB, Loukas A, Hofmann A. SBAL: a 842 
practical tool to generate and edit structure-based amino acid sequence alignments. 843 
Bioinformatics. 2012 Apr 1;28(7):1026–7.  844 
.CC-BY 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/641837doi: bioRxiv preprint first posted online May. 17, 2019; 
37 
 
45.  Lobley A, Sadowski MI, Jones DT. pGenTHREADER and pDomTHREADER: new 845 
methods for improved protein fold recognition and superfamily discrimination. Bioinformatics. 846 
2009 Jul 15;25(14):1761–7.  847 
46.  Jurrus E, Engel D, Star K, Monson K, Brandi J, Felberg LE, et al. Improvements to the 848 
APBS biomolecular solvation software suite. Protein Sci. 2018;27(1):112–28.  849 
47.  Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. 850 
UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem. 851 
2004 Oct;25(13):1605–12.  852 
48.  Dahiya N, Tewari R, Hoondal GS. Biotechnological aspects of chitinolytic enzymes: a 853 
review. Appl Microbiol Biotechnol. 2006 Aug 1;71(6):773–82.  854 
49.  Tachu B, Pillai S, Lucius R, Pogonka T. Essential Role of Chitinase in the Development 855 
of the Filarial Nematode Acanthocheilonema viteae. Infect Immun. 2008 Jan;76(1):221–8.  856 
50.  Gooyit M, Tricoche N, Lustigman S, Janda KD. Dual Protonophore–Chitinase 857 
Inhibitors Dramatically Affect O. volvulus Molting. J Med Chem. 2014 Jul 10;57(13):5792–9.  858 
51.  Sanders NL, Mishra A. Role of Interleukin-18 in the Pathophysiology of Allergic 859 
Diseases. Cytokine Growth Factor Rev. 2016 Dec;32:31–9.  860 
52.  Nair MG, Du Y, Perrigoue JG, Zaph C, Taylor JJ, Goldschmidt M, et al. Alternatively 861 
activated macrophage-derived RELM-α is a negative regulator of type 2 inflammation in the 862 
lung. The Journal of Experimental Medicine. 2009 Apr 13;206(4):937.  863 
53.  Sutherland TE, Rückerl D, Logan N, Duncan S, Wynn TA, Allen JE. Ym1 induces 864 
RELMα and rescues IL-4Rα deficiency in lung repair during nematode infection. PLOS 865 
Pathogens. 2018 Nov 30;14(11):e1007423.  866 
54.  Wolfs IMJ, Stöger JL, Goossens P, Pöttgens C, Gijbels MJJ, Wijnands E, et al. 867 
Reprogramming macrophages to an anti-inflammatory phenotype by helminth antigens reduces 868 
murine atherosclerosis. The FASEB Journal. 2013 Sep 16;28(1):288–99.  869 
.CC-BY 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/641837doi: bioRxiv preprint first posted online May. 17, 2019; 
38 
 
55.  Paterson JCM, Garside P, Kennedy MW, Lawrence CE. Modulation of a Heterologous 870 
Immune Response by the Products of Ascaris suum. Infect Immun. 2002 Nov;70(11):6058–67.  871 
56.  Hartmann S, Kyewski B, Sonnenburg B, Lucius R. A filarial cysteine protease inhibitor 872 
down-regulates T cell proliferation and enhances interleukin-10 production. Eur J Immunol. 873 
1997 Sep;27(9):2253–60.  874 
57.  Grainger JR, Smith KA, Hewitson JP, McSorley HJ, Harcus Y, Filbey KJ, et al. 875 
Helminth secretions induce de novo T cell Foxp3 expression and regulatory function through 876 
the TGF-β pathway. J Exp Med. 2010 Oct 25;207(11):2331–41.  877 
58.  Sutherland TE, Maizels RM, Allen JE. Chitinases and chitinase-like proteins: potential 878 
therapeutic targets for the treatment of T-helper type 2 allergies. Clinical & Experimental 879 
Allergy. 2009;39(7):943–55.  880 
59.  Olland AM, Strand J, Presman E, Czerwinski R, Joseph-McCarthy D, Krykbaev R, et 881 
al. Triad of polar residues implicated in pH specificity of acidic mammalian chitinase. Protein 882 
Sci. 2009 Mar;18(3):569–78.  883 
60.  Fusetti F, Moeller H von, Houston D, Rozeboom HJ, Dijkstra BW, Boot RG, et al. 884 
Structure of Human Chitotriosidase IMPLICATIONS FOR SPECIFIC INHIBITOR DESIGN 885 
AND FUNCTION OF MAMMALIAN CHITINASE-LIKE LECTINS. J Biol Chem. 2002 Jul 886 
12;277(28):25537–44.  887 
61.  Fusetti F, Pijning T, Kalk KH, Bos E, Dijkstra BW. Crystal Structure and Carbohydrate-888 
binding Properties of the Human Cartilage Glycoprotein-39. J Biol Chem. 2003 Sep 889 
26;278(39):37753–60.  890 
62.  Tsai M-L, Liaw S-H, Chang N-C. The crystal structure of Ym1 at 1.31Å resolution. 891 
Journal of Structural Biology. 2004 Dec 1;148(3):290–6.  892 
63.  Zhu Z, Zheng T, Homer RJ, Kim Y-K, Chen NY, Cohn L, et al. Acidic Mammalian 893 
Chitinase in Asthmatic Th2 Inflammation and IL-13 Pathway Activation. Science. 2004 Jun 894 
11;304(5677):1678–82.  895 
.CC-BY 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/641837doi: bioRxiv preprint first posted online May. 17, 2019; 
39 
 
64.  Yang C-J, Liu Y-K, Liu C-L, Shen C-N, Kuo M-L, Su C-C, et al. Inhibition of acidic 896 
mammalian chitinase by RNA interference suppresses ovalbumin-sensitized allergic asthma. 897 
Hum Gene Ther. 2009 Dec;20(12):1597–606.  898 
65.  Matsumoto T, Inoue H, Sato Y, Kita Y, Nakano T, Noda N, et al. Demethylallosamidin, 899 
a chitinase inhibitor, suppresses airway inflammation and hyperresponsiveness. Biochemical 900 
and Biophysical Research Communications. 2009 Dec 4;390(1):103–8.  901 
66.  Basyoni MMA, Rizk EMA. Nematodes ultrastructure: complex systems and processes. 902 
J Parasit Dis. 2016 Dec;40(4):1130–40.  903 
67.  Wang T, Van Steendam K, Dhaenens M, Vlaminck J, Deforce D, Jex AR, et al. 904 
Proteomic analysis of the excretory-secretory products from larval stages of Ascaris suum 905 
reveals high abundance of glycosyl hydrolases. PLoS Negl Trop Dis. 2013;7(10):e2467.  906 
68.  Hewitson JP, Harcus Y, Murray J, van Agtmaal M, Filbey KJ, Grainger JR, et al. 907 
Proteomic analysis of secretory products from the model gastrointestinal nematode 908 
Heligmosomoides polygyrus reveals dominance of Venom Allergen-Like (VAL) proteins. J 909 
Proteomics. 2011 Aug 24;74(9):1573–94.  910 
69.  Kradin RL, Badizadegan K, Auluck P, Korzenik J, Lauwers GY. Iatrogenic Trichuris 911 
suis Infection in a Patient With Crohn Disease. Archives of Pathology & Laboratory Medicine 912 
Online. 2009.  913 
70.  Chehayeb JF, Robertson AP, Martin RJ, Geary TG. Proteomic analysis of adult Ascaris 914 
suum fluid compartments and secretory products. PLoS Negl Trop Dis. 2014 Jun;8(6):e2939.  915 
71.  Hewitson JP, Harcus YM, Curwen RS, Dowle AA, Atmadja AK, Ashton PD, et al. The 916 
secretome of the filarial parasite, Brugia malayi: Proteomic profile of adult excretory–secretory 917 
products. Molecular and Biochemical Parasitology. 2008 Jul 1;160(1):8–21.  918 
72.  Cass CL, Johnson JR, Califf LL, Xu T, Hernandez HJ, Stadecker MJ, et al. Proteomic 919 
Analysis of Schistosoma mansoni Egg Secretions. Mol Biochem Parasitol. 2007 920 
Oct;155(2):84–93.  921 
.CC-BY 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/641837doi: bioRxiv preprint first posted online May. 17, 2019; 
40 
 
73.  Jex AR, Nejsum P, Schwarz EM, Hu L, Young ND, Hall RS, et al. Genome and 922 
transcriptome of the porcine whipworm Trichuris suis. Nat Genet. 2014 Jul;46(7):701–6.  923 
74.  Boot RG, Blommaart EFC, Swart E, Vlugt KG der, Bijl N, Moe C, et al. Identification 924 
of a Novel Acidic Mammalian Chitinase Distinct from Chitotriosidase. J Biol Chem. 2001 Mar 925 
2;276(9):6770–8.  926 
75.  Okawa K, Ohno M, Kashimura A, Kimura M, Kobayashi Y, Sakaguchi M, et al. Loss 927 
and Gain of Human Acidic Mammalian Chitinase Activity by Nonsynonymous SNPs. Mol Biol 928 
Evol. 2016 Dec;33(12):3183–93.  929 
76.  Hamid R, Khan MA, Ahmad M, Ahmad MM, Abdin MZ, Musarrat J, et al. Chitinases: 930 
An update. J Pharm Bioallied Sci. 2013;5(1):21–9.  931 
77.  Wu Y, Egerton G, Underwood AP, Sakuda S, Bianco AE. Expression and Secretion of 932 
a Larval-specific Chitinase (Family 18 Glycosyl Hydrolase) by the Infective Stages of the 933 
Parasitic Nematode, Onchocerca volvulus. J Biol Chem. 2001 Nov 9;276(45):42557–64.  934 
78.  Wu Y, Adam R, Williams SA, Bianco AE. Chitinase genes expressed by infective larvae 935 
of the filarial nematodes, Acanthocheilonema viteae and Onchocerca volvulus. Molecular and 936 
Biochemical Parasitology. 1996 Jan 1;75(2):207–19.  937 
79.  Fuhrman JA, Lane WS, Smith RF, Piessens WF, Perler FB. Transmission-blocking 938 
antibodies recognize microfilarial chitinase in brugian lymphatic filariasis. PNAS. 1992 Mar 939 
1;89(5):1548–52.  940 
80.  Adam R, Kaltmann B, Rudin W, Friedrich T, Marti T, Lucius R. Identification of 941 
Chitinase as the Immunodominant Filarial Antigen Recognized by Sera of Vaccinated Rodents. 942 
J Biol Chem. 1996 Jan 19;271(3):1441–7.  943 
81.  Ward KA, Fairbairn D. Chitinase in Developing Eggs of Ascaris suum (Nematoda). The 944 
Journal of Parasitology. 1972;58(3):546–9.  945 
.CC-BY 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/641837doi: bioRxiv preprint first posted online May. 17, 2019; 
41 
 
82.  Zimmermann N, Mishra A, King NE, Fulkerson PC, Doepker MP, Nikolaidis NM, et 946 
al. Transcript Signatures in Experimental Asthma: Identification of STAT6-Dependent and -947 
Independent Pathways. The Journal of Immunology. 2004 Feb 1;172(3):1815–24.  948 
83.  Zhao J, Zhu H, Wong CH, Leung KY, Wong WSF. Increased lungkine and chitinase 949 
levels in allergic airway inflammation: A proteomics approach. PROTEOMICS. 950 
2005;5(11):2799–807.  951 
84.  Lee I-A, Low D, Kamba A, Llado V, Mizoguchi E. Oral caffeine administration 952 
ameliorates acute colitis by suppressing chitinase 3-like 1 expression in intestinal epithelial 953 
cells. J Gastroenterol. 2014 Aug;49(8):1206–16.  954 
85.  Hartl D, He CH, Koller B, Da Silva CA, Homer R, Lee CG, et al. Acidic Mammalian 955 
Chitinase Is Secreted via an ADAM17/Epidermal Growth  Factor Receptor-dependent Pathway 956 
and Stimulates Chemokine Production by  Pulmonary Epithelial  Cells. J Biol Chem. 2008 Nov 957 
28;283(48):33472–82.  958 
86.  Hartl D, He CH, Koller B, Da Silva CA, Kobayashi Y, Lee CG, et al. Acidic Mammalian 959 
Chitinase Regulates Epithelial Cell via a Chitinolytic-Independent Mechanism. J Immunol. 960 
2009 Apr 15;182(8):5098–106.  961 
87.  Robinson MW, Donnelly S, Hutchinson AT, To J, Taylor NL, Norton RS, et al. A 962 
Family of Helminth Molecules that Modulate Innate Cell Responses via Molecular Mimicry of 963 
Host Antimicrobial Peptides. PLoS Pathog. 2011 May 12;7(5). 88.  Huang X, Zeng L-R, 964 
Chen F-S, Zhu J-P, Zhu M-H. Trichuris suis ova therapy in inflammatory bowel disease. 965 
Medicine (Baltimore). 2018 Aug 24 ;97(34).  966 
 967 
Figures and Figure captions 968 
.CC-BY 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/641837doi: bioRxiv preprint first posted online May. 17, 2019; 
42 
 
 969 
Figure 1. T. suis L1 ES proteins are highly stage-specific and candidates reduce allergic 970 
airway hyperreactivity when recombinantly expressed and applied. (A) Protein ID counts 971 
resulting from proteomic MS-based analysis (see Supplementary Table S1) were compared 972 
across the proteomic datasets of T. suis L1, L2, L3 and L4 ES proteins. Shown are protein IDs 973 
selected for recombinant expression. (B) Expression cassette of LEXSY eukaryotic 974 
expression system illustrating positioning of the export signal peptide that mediates secretion 975 
(SP), the selection antibiotic (nourseothricin, NTC) and the His6-tag for purification (H6). The 976 
cassette was integrated into the L. tarentolae genome. (C) Silver-stained SDS/PAGE gel of 977 
recombinantly expressed T. suis L1 proteins. (D) Experimental set-up of acute ovalbumin-978 
(OVA)-induced allergic airway hyperreactivity model and treatment regimen with 979 
recombinant T. suis proteins. Animals were OVA-sensitized on days 0 and 14 and challenged 980 
with OVA intranasally on days 28 and 29. BAL fluid was collected from pretreated or 981 
untreated animals at day 31. (E) Total number of cellular infiltrates in BAL fluid. Shown are 982 
non-allergic mice (PBS controls), untreated allergic mice (OVA) and treatments with 983 
recombinant T. suis proteins indicated by GenBank IDs. (F) Numbers of eosinophils in BAL 984 
fluid detected by differential cell counts of cytospin preparations stained with DiffQuick over 985 
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the different treatment groups. Data shown are mean + SEM of n = 5–10 animals from 2 986 
separate experiments. Statistically significant differences were determined using a Kruskal-987 
Wallis test (Dunn’s multiple comparisons test) and are indicated, * p ≤ 0.05. 988 
 989 
 990 
Figure 2. KFD48490.1 is an active chitinase. (A) KFD48490.1 amino acid sequence with 991 
mapped signal peptide (bold, red), catalytically active residues (highlighted in blue/bold red) 992 
and the chitin-binding domain (bold, black, italic). (B) Amino acid sequence alignment of 993 
KFD48490.1 and known nematode chitinases. (C) Fluorimetric chitinase assay testing 994 
recombinant KFD48490.1, heat-inactivated KFD48490.1 and a chitinase control enzyme (ctrl) 995 
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with substrates for endochitinase (left) and exochitinase (right) activity. Data shown are mean 996 
± SD of n = 3 replicates from one of three independent experiments. (D) Chitinase assay testing 997 
KFD48490.1 activity depending on pH (range 2-10). (E) Chitinase assay testing KFD48490.1 998 
pre-incubated at different temperatures (4–90 °C) for 1 h prior to the assay. Data shown are 999 
mean ± SD of n = 3 replicates. 1000 
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 1001 
Figure 3. Ts_Chit treatment mediates attenuation of airway hyperreactivity. Bronchoalveolar 1002 
lavage (BAL) was performed two days after OVA challenge and the BAL fluid was examined 1003 
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for (A) total number of infiltrating cells (Neubauer chamber), (B) BAL eosinophils, (C) BAL 1004 
neutrophils and (D) monocytes/macrophages using cytospin preparations and DiffQuick 1005 
staining. (E) Representative plots of BAL infiltrating cells using flow cytometry and focusing 1006 
on eosinophil frequencies (identified as CD45+CD11b+GR1lowCD11c-SiglecF+). Summary of 1007 
flow cytometric analysis of (F) BAL eosinophils and (G) alveolar macrophages 1008 
(CD45+CD11blowCD11c+). (H) Basal expiration time during PBS inhalation measured using 1009 
whole-body double-chamber plethysmography 24 h after OVA challenge. (I) Concentration 1010 
response curve of methacholine sensitivity. Specific airway resistance (Sraw) was assessed in 1011 
response to increasing doses of methacholine. (J) Sraw values recorded when nebulizing 1012 
50 mg/ml of methacholine. (K) BAL cytokines detected two days after challenge using bead-1013 
based multiplexing. A-K data are presented as mean ± SEM of n = 10–12 animals from n = 3 1014 
separate experiments. Statistical significance was assessed using a two-tailed Mann-Whitney 1015 
test and results are indicated by * p ≤  0.05, ** p ≤ 0.01, *** p ≤  0.001. 1016 
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 1017 
Figure 4. Ts-Chit -mediated effects on lung parenchymal macrophages. (A) Histopathological 1018 
evaluation of tissue inflammation. (B) Histological sections of paraffin-embedded lung tissues 1019 
from treated (Ts-Chit and Ts-Chit inact.), untreated (OVA) and non-sensitized (PBS) controls 1020 
stained for RELMα (red) and haematoxylin (steelblue) and presented at 400× magnification. 1021 
(C) Histological quantification of interstitial RELMα+ cells. (D) Gating strategy and 1022 
representative plots of RELMα+ macrophages (EpCAM-CD11c+CD64+MHCII+Siglec-) of lung 1023 
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homogenates from OVA-sensitized and challenged mice with or without Ts-Chit treatment 1024 
summarized in (E) and (F). (G) mRNA expression of arginase-1, monocyte chemotactic 1025 
protein 1 (MCP1/CCL-2) and CCL-11/Eotaxin in lung tissue samples of mice from challenge 1026 
experiments after lung lavage. Expression was normalized by using the housekeeper gene 1027 
peptidyl prolylisomerase A (PPIA) and is presented as fold difference to the PBS control group. 1028 
A, C, G data are presented as mean + SEM of n = 10–12 animals from n = 3 separate 1029 
experiments. D-F data are generated from n = 4–5 mice from one experiment. Statistical 1030 
significance was assessed using a two-tailed Mann-Whitney test and is indicated by * p ≤ 0.05, 1031 
** p ≤ 0.01. 1032 
  1033 
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 1034 
 1035 
Figure 5. Three-dimensional structure of T. suis chitinase (Ts_Chit). (A) Overall structure of 1036 
Ts-Chit forming a C2-symmetric dimer [α-helices in red, ß-strands in blue] The inset A.1 1037 
depicts the dimer-stabilizing disulphide bond-forming cysteine residue at position 180, while 1038 
the inset A.2 highlights the catalytic DxDxE center. (B) Ts-Chit dimer rotated by 90° compared 1039 
to (A). (C) Ts-Chit monomer and its structural alignment with AMCase (PDB Id 3FXY, (59)), 1040 
human Chit1 (PDB-Id 1GUV, (60)), human YKL-40 (PDB-Id 1NWR, (61)) and murine Ym1 1041 
(PDB-Id 1VF8, (62)). (D) Silver stained SDS/PAGE gel of recombinantly expressed Ts-Chit (1 1042 
µg) under reducing (+ß-Merc.) and non-reducing (-ß-Merc.) loading conditions. 1043 
 1044 
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 1045 
Figure 6. Electrostatic surface representation of murine AMCase (PDB 3FY1) and the Ts-Chit 1046 
dimer. (A) Upper panel: In the Ts-Chit dimer, a surface patch of similar charge and shape as 1047 
observed in murine AMCase is formed. The similar, acidic surface patch in both molecules is 1048 
circled. Lower panel: Cartoon rendering of murine AMCase and Ts-Chit in the same orientation 1049 
as in the upper panel. The location of the circled residues in AMCase are highlighted in blue. 1050 
Helices α3 and α4 contributing to the dimer formation in Ts-Chit are colored turquoise and 1051 
orange, respectively. The surface electrostatics were calculated with APBS and visualized with 1052 
UCSF Chimera. 1053 
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 1054 
Figure 7. Ts-Chit treatment results in antibody responses against murine AMCase and 1055 
BRP-39 and interferes with murine chitinase activity. (A) Chitinase assay testing BAL 1056 
samples of allergic mice with endochitinase substrate. Data shown are mean + SEM of n = 4–1057 
5 replicates. (B) mRNA expression of murine chitinase AMCase (Chia1) in lung tissue samples 1058 
of mice from AHR challenge experiments after lung lavage. Expression was normalized by 1059 
using the housekeeper gene peptidyl prolylisomerase A (PPIA) and is presented as fold 1060 
difference to the PBS group. Data are presented as mean + SEM of n = 12 animals from n = 3 1061 
separate experiments. Data were analysed statistically using an unpaired t-test. (C) Western 1062 
blot of recombinantly expressed murine AMCase, murine CLPs and Ts-Chit. Top blot of 1063 
SDS/PAGE shows detection of recombinant proteins by anti-His6 antibody (1:200) after loading 1064 
20 µl of AMCase-, Ym1-, Ym2-, and BRP-39-transfected COS7 cell supernatants, 0.125 µg 1065 
Ts-Chit and 0.2 µg p53 control protein. As negative control, supernatants of non-transfected 1066 
COS7 cells were used (-ctrl). Middle blot shows murine chitinase and CLP loading, but 1067 
incubation with serum antibodies from Ts-Chit treated, OVA-sensitized and challenged mice 1068 
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(1:100) and detection using anti-mouse IgG-HRP (1:2500). Bottom blot shows identical loading 1069 
including one lane for OVA protein (0.5 µg) as positive control and incubation with serum 1070 
antibodies from untreated, allergic (OVA) mice (1:100) detected using anti-mouse IgG-HRP 1071 
(1:2500). For serum incubation, sera of n = 4 mice were pooled and representative Western 1072 
blots from n = 3 separate experiments are shown. 1073 
 1074 
.CC-BY 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/641837doi: bioRxiv preprint first posted online May. 17, 2019; 
Table S1: Mass spectrometric identification of T. suis  larvae ES proteins. 
Precipitated proteins were reduced, alkylated, tryptic digested and analyzed by LC-MSMS and Mascot searches against NCBI database.
Significant hits (+) were identified with > 2 peptides (p< 0.01), non-significant candidates (c) are also listed.
Homologous proteins are grouped to the same #-number.
# Protein name NCBI-ID L1 10dpi 18dpi 28dpi
1_1 astacin [Trichuris suis] KHJ43437.1 +
1_2 hypothetical protein M513_10127 [Trichuris suis] KFD48975.1 +
2_1 hypothetical protein D918_10164 [Trichuris suis] KHJ39810.1 +
2_2 hypothetical protein M513_00865 [Trichuris suis] KFD58102.1 +
2_3 hypothetical protein M514_00865 [Trichuris suis] KFD61181.1 +
3_1 hypothetical protein M513_06373 [Trichuris suis] KFD52717.1 + c
3_2 serine proteinase inhibitor [Trichuris suis] KHJ48406.1 + c
4_1 chitin binding Peritrophin-A domain protein [Trichuris suis] KHJ46953.1 +
4_2 hypothetical protein M513_10624 [Trichuris suis] KFD48490.1 +
4_3 hypothetical protein M514_10624, partial [Trichuris suis] KFD69702.1 +
5_1 hypothetical protein D918_01317 [Trichuris suis] KHJ48050.1 + c
5_2 hypothetical protein M513_03477 [Trichuris suis] KFD55729.1 + c
6_1 hypothetical protein M513_01545 [Trichuris suis] KFD57442.1 + +
6_2 hypothetical protein M514_01545 [Trichuris suis] KFD66550.1 + +
7_1 chitinase class I [Trichuris suis] KHJ45348.1 +
7_2 hypothetical protein M513_11522 [Trichuris suis] KFD47603.1 +
7_3 hypothetical protein M514_11522 [Trichuris suis] KFD67631.1 +
8_1 hypothetical protein D918_02479 [Trichuris suis] KHJ46940.1 +
8_3 hypothetical protein M513_13299 [Trichuris suis] KFD45818.1 +
9_1 copper/zinc superoxide dismutase [Trichuris suis] KHJ41357.1 +
9_2 hypothetical protein M513_05621 [Trichuris suis] KFD53515.1 +
9_3 hypothetical protein M514_05621 [Trichuris suis] KFD71814.1 +
10_1 hypothetical protein M513_11481 [Trichuris suis] KFD47618.1 +
10_2 hypothetical protein M514_11481 [Trichuris suis] KFD72328.1 +
11 hypothetical protein M513_05526 [Trichuris suis] KFD53610.1 + +
12 hypothetical protein M513_01533 [Trichuris suis] KFD57430.1 + +
13 hypothetical protein M513_07350, partial [Trichuris suis] KFD51823.1 + +
14 hypothetical protein M513_00025 [Trichuris suis] KFD58862.1 + +
15 hypothetical protein M513_05372 [Trichuris suis] KFD53667.1 + c
16 hypothetical protein M513_05523, partial [Trichuris suis] KFD53607.1 +
17 hypothetical protein M513_04236 [Trichuris suis] KFD54802.1 +
18 hypothetical protein M513_13623 [Trichuris suis] KFD45500.1 +
19 hypothetical protein M513_04624 [Trichuris suis] KFD54477.1 +
20 hypothetical protein M513_09085 [Trichuris suis] KFD49992.1 c + + +
21 hypothetical protein M513_04701 [Trichuris suis] KFD54358.1 c + + +
22 hypothetical protein M513_06879 [Trichuris suis] KFD52316.1 c +
23_1 hypothetical protein M514_10152 [Trichuris suis] KFD62925.1 c c + +
23_2 hypothetical protein M513_10152 [Trichuris suis] KFD49000.1 c c
24_1 hypothetical protein M513_01669 [Trichuris suis] KFD57566.1 c c
24_2 hypothetical protein M514_01669 [Trichuris suis] KFD64855.1 c c
25_1 hypothetical protein M514_24957 [Trichuris suis] KFD62836.1 c c
25_2 hypothetical protein M513_03628 [Trichuris suis] KFD55576.1 c
25_3 hypothetical protein M513_03629 [Trichuris suis] KFD55577.1 c
25_4 hypothetical protein M514_03629, partial [Trichuris suis] KFD59516.1 c
26 hypothetical protein D918_04545 [Trichuris suis] KHJ45241.1 c c
27 hypothetical protein M513_01541 [Trichuris suis] KFD57438.1 c c
28 hypothetical protein M513_00679 [Trichuris suis] KFD58453.1 c
29_1 hypothetical protein M513_11174 [Trichuris suis] KFD47941.1 + + +
29_2 hypothetical protein M513_11839 [Trichuris suis] KFD47286.1 + + +
29_3 hypothetical protein M514_23670 [Trichuris suis] KFD64181.1 + + c
29_4 hypothetical protein M514_27543 [Trichuris suis] KFD60271.1 + + +
30_1 hypothetical protein M513_03282 [Trichuris suis] KFD55843.1 + + +
30_2 hypothetical protein M514_03282 [Trichuris suis] KFD70192.1 + + +
30_3 kinase domain protein [Trichuris suis] KHJ49431.1 +
31_1 hypothetical protein M513_07694 [Trichuris suis] KFD51481.1 + + +
31_2 hypothetical protein M514_07694 [Trichuris suis] KFD61942.1 + + +
32_1 hypothetical protein M513_03048 [Trichuris suis] KFD55924.1 + + +
32_2 hypothetical protein M514_03048, partial [Trichuris suis] KFD68317.1 + + +
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32_3 trypsin Inhibitor like cysteine rich domain protein [Trichuris suis] KHJ43166.1 + + +
33_1 hypothetical protein M513_05555 [Trichuris suis] KFD53639.1 + c c
33_2 hypothetical protein D918_02595 [Trichuris suis] KHJ47049.1 c c c
34_1 hypothetical protein D918_03253 [Trichuris suis] KHJ46205.1 + c
34_2 hypothetical protein M513_07983 [Trichuris suis] KFD51083.1 + c
35_1 hypothetical protein M514_03300, partial [Trichuris suis] KFD70210.1 + +
35_2 hypothetical protein D918_06438 [Trichuris suis] KHJ43528.1 c +
36_1 hypothetical protein M513_09923 [Trichuris suis] KFD49201.1 + c
36_2 SCP-like protein [Trichuris suis] KHJ49366.1 + c
36_3 hypothetical protein M513_04750 [Trichuris suis] KFD54407.1 c
37_1 dipeptidyl carboxydipeptidase family protein [Trichuris suis] KHJ48157.1 + c
37_2 hypothetical protein M513_07445 [Trichuris suis] KFD51748.1 + c
37_3 hypothetical protein M514_07445 [Trichuris suis] KFD67136.1 + c
38_1 hypothetical protein M513_12276 [Trichuris suis] KFD46830.1 + c
38_2 hypothetical protein M514_12276 [Trichuris suis] KFD64998.1 + c
39_1 hypothetical protein M513_01631 [Trichuris suis] KFD57528.1 + c c
39_2 hypothetical protein M514_01631 [Trichuris suis] KFD63563.1 + c c
40_1 glycerol-3-phosphate dehydrogenase [NAD(P)+ ] [Trichuris suis] KHJ43845.1 + + c
40_2 hypothetical protein M513_02985, partial [Trichuris suis] KFD56207.1 + + +
41_1 hypothetical protein M514_13515 [Trichuris suis] KFD64188.1 + c
41_2 hypothetical protein M513_11170 [Trichuris suis] KFD47937.1 c
42_1 hypothetical protein M514_12219 [Trichuris suis] KFD60943.1 + + +
42_2 hypothetical protein M513_12222 [Trichuris suis] KFD46900.1 c +
43_1 hypothetical protein M514_12825 [Trichuris suis] KFD62209.1 + +
43_2 hypothetical protein M513_12827 [Trichuris suis] KFD46292.1 c +
43_3 hypothetical protein D918_04921 [Trichuris suis] KHJ44687.1 c
44_1 hypothetical protein M514_28048 [Trichuris suis] KFD59771.1 + c c
44_2 hypothetical protein M513_13257, partial [Trichuris suis] KFD45867.1 c c
45_1 hypothetical protein M513_01063 [Trichuris suis] KFD58300.1 + + +
45_2 5'-nucleotidase protein [Trichuris suis] KHJ47404.1 +
45_3 hypothetical protein D918_04345 [Trichuris suis] KHJ45608.1 c
45_4 hypothetical protein M513_04837 [Trichuris suis] KFD54295.1 c
46_1 hypothetical protein D918_06825 [Trichuris suis] KHJ42968.1 +
46_2 hypothetical protein M513_08123 [Trichuris suis] KFD50941.1 +
47_1 hypothetical protein D918_09642 [Trichuris suis] KHJ40336.1 +
47_2 hypothetical protein M513_10945 [Trichuris suis] KFD48159.1 +
47_3 hypothetical protein M514_10945 [Trichuris suis] KFD61896.1 +
48_1 hypothetical protein M513_04629 [Trichuris suis] KFD54482.1 +
48_2 hypothetical protein M514_04629 [Trichuris suis] KFD73347.1 +
49_1 deoxyribonuclease II [Trichuris suis] KHJ48080.1 + c c
49_2 hypothetical protein M513_01156 [Trichuris suis] KFD57923.1 +
49_3 hypothetical protein M514_17021 [Trichuris suis] KFD70899.1 +
50_1 hypothetical protein D918_02817 [Trichuris suis] KHJ47243.1 +
50_2 hypothetical protein M513_13694 [Trichuris suis] KFD45428.1 +
50_3 hypothetical protein M514_13694 [Trichuris suis] KFD60175.1 +
50_4 hypothetical protein M514_25363 [Trichuris suis] KFD62430.1 +
51_1 hypothetical protein M513_05301 [Trichuris suis] KFD53795.1 +
51_2 hypothetical protein M514_05301 [Trichuris suis] KFD71589.1 +
52_1 eukaryotic aspartyl protease [Trichuris suis] KHJ46445.1 +
52_2 hypothetical protein M513_01139 [Trichuris suis] KFD57906.1 +
52_3 hypothetical protein M514_01139, partial [Trichuris suis] KFD70919.1 +
53 hypothetical protein M514_18642 [Trichuris suis] KFD69065.1 + + +
54 hypothetical protein M513_04702 [Trichuris suis] KFD54359.1 + c +
55 hypothetical protein M513_02643 [Trichuris suis] KFD56539.1 + c +
56 hypothetical protein M513_05339 [Trichuris suis] KFD53833.1 + + +
57 hypothetical protein M513_12223, partial [Trichuris suis] KFD46901.1 + + +
58 hypothetical protein D918_01923 [Trichuris suis] KHJ47765.1 + +
59 hypothetical protein M513_05264, partial [Trichuris suis] KFD53758.1 + c c
60 hypothetical protein M514_27940 [Trichuris suis] KFD59881.1 + c
61 hypothetical protein M513_01283 [Trichuris suis] KFD58050.1 + c
62 hypothetical protein M513_08967, partial [Trichuris suis] KFD50128.1 + c
63 hypothetical protein M513_01523 [Trichuris suis] KFD57420.1 +
64 hypothetical protein M514_10707 [Trichuris suis] KFD62439.1 +
65 hypothetical protein M513_06133 [Trichuris suis] KFD53017.1 +
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66 hypothetical protein M513_03688 [Trichuris suis] KFD55348.1 +
67 hypothetical protein M513_01548 [Trichuris suis] KFD57445.1 +
68 hypothetical protein M513_10380 [Trichuris suis] KFD48750.1 +
69 hypothetical protein M514_15631 [Trichuris suis] KFD72358.1 +
70 hypothetical protein M513_05720 [Trichuris suis] KFD53456.1 +
71 hypothetical protein M513_13062 [Trichuris suis] KFD46058.1 +
72 hypothetical protein M513_09650 [Trichuris suis] KFD49465.1 +
73 hypothetical protein M514_11842 [Trichuris suis] KFD60275.1 +
74 hypothetical protein M513_09708 [Trichuris suis] KFD49441.1 +
75 hypothetical protein M513_13311 [Trichuris suis] KFD45809.1 +
76_1 hypothetical protein M514_06559 [Trichuris suis] KFD65215.1 c + +
76_2 hypothetical protein M513_06559 [Trichuris suis] KFD52525.1 c +
76_3 hypothetical protein D918_09267 [Trichuris suis] KHJ40675.1 c
77_1 hypothetical protein D918_02980 [Trichuris suis] KHJ46659.1 c c +
77_2 hypothetical protein M513_09161 [Trichuris suis] KFD49947.1 c c +
78_1 hypothetical protein M513_07011 [Trichuris suis] KFD52166.1 c + +
78_2 hypothetical protein M514_07011 [Trichuris suis] KFD65195.1 c + +
79_1 hypothetical protein M513_11843 [Trichuris suis] KFD47290.1 c c
79_2 hypothetical protein M514_11843 [Trichuris suis] KFD60276.1 c c
80_1 hypothetical protein M513_08977 [Trichuris suis] KFD50138.1 c c c
80_2 hypothetical protein M514_08977 [Trichuris suis] KFD70020.1 c c c
81_1 hypothetical protein D918_01088 [Trichuris suis] KHJ48783.1 c c
81_2 hypothetical protein M513_04058 [Trichuris suis] KFD55140.1 c c
82_1 hypothetical protein M513_03843 [Trichuris suis] KFD55202.1 c + c
82_2 hypothetical protein M514_22380 [Trichuris suis] KFD65454.1 c + c
83_1 hypothetical protein M513_08058 [Trichuris suis] KFD51017.1 c c c
83_2 hypothetical protein M514_08058 [Trichuris suis] KFD73230.1 c c c
84_1 hypothetical protein D918_06364 [Trichuris suis] KHJ43455.1 c c
84_2 hypothetical protein M513_13969 [Trichuris suis] KFD45154.1 c c
84_3 hypothetical protein M514_13969 [Trichuris suis] KFD60414.1 c c
85 nematode cuticle collagen domain protein [Trichuris suis] KHJ49255.1 c c c
86_1 hypothetical protein M513_13381 [Trichuris suis] KFD45741.1 c c
86_2 hypothetical protein M514_13381 [Trichuris suis] KFD69755.1 c c
87_1 hypothetical protein M513_13112 [Trichuris suis] KFD46010.1 c + +
87_2 hypothetical protein M514_13112 [Trichuris suis] KFD61255.1 c + +
88_1 hypothetical protein M514_01527 [Trichuris suis] KFD66530.1 c c +
88_2 hypothetical protein M513_01527 [Trichuris suis] KFD57424.1 c c +
88_3 hypothetical protein D918_00204, partial [Trichuris suis] KHJ49086.1 c
89_1 hypothetical protein D918_08127 [Trichuris suis] KHJ41756.1 c c
89_2 hypothetical protein M513_10856 [Trichuris suis] KFD48279.1 c c
90_1 hypothetical protein D918_03106 [Trichuris suis] KHJ46759.1 c
90_2 hypothetical protein M513_07603 [Trichuris suis] KFD51553.1 c
90_3 hypothetical protein M514_07603 [Trichuris suis] KFD65633.1 c
91_1 hypothetical protein D918_04548 [Trichuris suis] KHJ45244.1 c
91_2 hypothetical protein M513_03842 [Trichuris suis] KFD55201.1 c
91_3 hypothetical protein M514_03842 [Trichuris suis] KFD65453.1 c
92_1 hypothetical protein M513_03423 [Trichuris suis] KFD55675.1 c
92_2 WAP-type 'four-disulfide core [Trichuris suis] KHJ48262.1 c
93_1 cathepsin propeptide inhibitor domain protein [Trichuris suis] KHJ41450.1 c
93_2 hypothetical protein M513_07451 [Trichuris suis] KFD51754.1 c
94_1 hypothetical protein M513_11177 [Trichuris suis] KFD47944.1 c
94_2 hypothetical protein M514_11177, partial [Trichuris suis] KFD64176.1 c
95_1 hypothetical protein D918_04979 [Trichuris suis] KHJ44744.1 c
95_2 hypothetical protein M513_06970 [Trichuris suis] KFD52125.1 c
95_3 hypothetical protein M514_06970 [Trichuris suis] KFD61632.1 c
96_1 hypothetical protein D918_02126 [Trichuris suis] KHJ47266.1 c
96_2 hypothetical protein M513_02266, partial [Trichuris suis] KFD57009.1 c
96_3 hypothetical protein M514_02266, partial [Trichuris suis] KFD70106.1 c
97_1 hypothetical protein D918_04420 [Trichuris suis] KHJ45116.1 c
97_2 hypothetical protein M513_09697 [Trichuris suis] KFD49430.1 c
97_3 hypothetical protein M514_24178 [Trichuris suis] KFD63646.1 c
98 hypothetical protein M513_05014 [Trichuris suis] KFD53995.1 c + +
99 hypothetical protein M513_07304 [Trichuris suis] KFD51777.1 c +
100 hypothetical protein M513_01916 [Trichuris suis] KFD57031.1 c c c
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101 hypothetical protein M513_10504 [Trichuris suis] KFD48649.1 c +
102 hypothetical protein M513_13254 [Trichuris suis] KFD45864.1 c +
103 hypothetical protein M513_02878 [Trichuris suis] KFD56100.1 c c c
104 hypothetical protein M513_07012 [Trichuris suis] KFD52167.1 c c
105 Carboxylesterase [Trichuris suis] KHJ48427.1 c
106 hypothetical protein M513_13834 [Trichuris suis] KFD45288.1 c
107 hypothetical protein M513_00705 [Trichuris suis] KFD58479.1 c
108 hypothetical protein M513_00638 [Trichuris suis] KFD58412.1 c
109 hypothetical protein M513_01343, partial [Trichuris suis] KFD57673.1 c
110 hypothetical protein M513_02830 [Trichuris suis] KFD56375.1 c
111 hypothetical protein M513_04328 [Trichuris suis] KFD54894.1 c
112_1 hypothetical protein M513_07066 [Trichuris suis] KFD52084.1 + +
112_2 hypothetical protein M514_07066 [Trichuris suis] KFD65846.1 + +
113_1 hypothetical protein M513_03361 [Trichuris suis] KFD55613.1 + +
113_2 hypothetical protein M514_03361 [Trichuris suis] KFD68024.1 + +
114_1 hypothetical protein M513_08330 [Trichuris suis] KFD50789.1 c +
114_2 hypothetical protein M514_08330 [Trichuris suis] KFD63404.1 c +
115_1 hypothetical protein M513_13670 [Trichuris suis] KFD45454.1 c +
115_2 hypothetical protein M514_13670 [Trichuris suis] KFD67510.1 c +
116_1 hypothetical protein M513_01531 [Trichuris suis] KFD57428.1 + +
116_2 hypothetical protein M514_01531 [Trichuris suis] KFD66534.1 + +
117_1 hypothetical protein D918_07287 [Trichuris suis] KHJ42568.1 c +
117_2 hypothetical protein M513_03657 [Trichuris suis] KFD55317.1 c +
117_3 hypothetical protein M514_03657 [Trichuris suis] KFD59705.1 c +
118_1 hypothetical protein M513_10502 [Trichuris suis] KFD48647.1 + +
118_2 hypothetical protein M514_10502 [Trichuris suis] KFD62239.1 + +
119_1 hypothetical protein D918_06254 [Trichuris suis] KHJ43749.1 +
119_2 hypothetical protein M513_06011 [Trichuris suis] KFD53097.1 +
119_3 hypothetical protein M514_06012 [Trichuris suis] KFD70755.1 c
120_1 hypothetical protein M513_07662 [Trichuris suis] KFD51449.1 c +
120_2 hypothetical protein M514_07662 [Trichuris suis] KFD65775.1 c +
121_1 hypothetical protein D918_00205 [Trichuris suis] KHJ49087.1 c c
121_2 hypothetical protein M513_01529 [Trichuris suis] KFD57426.1 c +
121_3 hypothetical protein M514_01529 [Trichuris suis] KFD66532.1 c +
122_1 hypothetical protein M513_01155 [Trichuris suis] KFD57922.1 c c
122_2 hypothetical protein M514_17022 [Trichuris suis] KFD70900.1 c c
123_1 hypothetical protein M513_05968 [Trichuris suis] KFD53054.1 c
123_2 hypothetical protein M513_05970 [Trichuris suis] KFD53056.1 c
123_3 hypothetical protein M514_27538 [Trichuris suis] KFD60285.1 c
124_1 hypothetical protein M513_09721 [Trichuris suis] KFD49358.1 c
124_2 hypothetical protein M514_13659 [Trichuris suis] KFD64576.1 c
125_1 hypothetical protein D918_04914 [Trichuris suis] KHJ44680.1 c
125_2 hypothetical protein M513_12191 [Trichuris suis] KFD46945.1 c
125_3 hypothetical protein M514_12191 [Trichuris suis] KFD62216.1 c
126_1 hypothetical protein D918_05935 [Trichuris suis] KHJ43882.1 c
126_2 hypothetical protein M513_02959 [Trichuris suis] KFD56181.1 c
127_1 hypothetical protein D918_02591 [Trichuris suis] KHJ47045.1 + c
127_2 hypothetical protein M514_05551, partial [Trichuris suis] KFD62628.1 + c
128_1 collagen triple helix repeat protein [Trichuris suis] KHJ49597.1 c c
128_2 hypothetical protein M513_08053 [Trichuris suis] KFD51012.1 c c
129_1 hypothetical protein M513_06427 [Trichuris suis] KFD52771.1 c
129_2 hypothetical protein M514_27457, partial [Trichuris suis] KFD60372.1 c
130_1 hypothetical protein D918_08193 [Trichuris suis] KHJ41663.1 c c
130_2 hypothetical protein M513_06801 [Trichuris suis] KFD52238.1 c c
130_3 hypothetical protein M514_06801 [Trichuris suis] KFD66698.1 c c
131_1 hypothetical protein D918_00794 [Trichuris suis] KHJ48492.1 c
131_2 hypothetical protein M513_09606 [Trichuris suis] KFD49495.1 c
131_3 hypothetical protein M514_09606 [Trichuris suis] KFD65669.1 c
132_1 hypothetical protein M513_02956 [Trichuris suis] KFD56178.1 + +
132_2 Kunitz/Bovine pancreatic trypsin inhibitor domain protein [Trichuris suis] KHJ47348.1 + +
133_1 hypothetical protein D918_03205 [Trichuris suis] KHJ46832.1 + +
133_2 hypothetical protein M513_13363 [Trichuris suis] KFD45757.1 c +
133_3 hypothetical protein M514_20584 [Trichuris suis] KFD67148.1 c +
134_1 hypothetical protein M513_07111 [Trichuris suis] KFD51979.1 +
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134_2 hypothetical protein M513_14229, partial [Trichuris suis] KFD44894.1 +
134_3 hypothetical protein M514_07111 [Trichuris suis] KFD71407.1 +
135_1 hypothetical protein M513_11184 [Trichuris suis] KFD47951.1 c
135_2 hypothetical protein M514_28192 [Trichuris suis] KFD59628.1 c
136_1 hypothetical protein D918_03945 [Trichuris suis] KHJ45733.1 c
136_2 hypothetical protein M513_01096 [Trichuris suis] KFD57863.1 c
137_1 hypothetical protein M513_13760 [Trichuris suis] KFD45364.1 c
137_2 hypothetical protein M514_27479 [Trichuris suis] KFD60349.1 c
137_3 molybdenum cofactor biosynthesis protein A [Trichuris suis] KHJ46840.1 c
138_1 hypothetical protein M514_12087 [Trichuris suis] KFD67515.1 + +
138_2 hypothetical protein M514_24411 [Trichuris suis] KFD63390.1 + +
138_3 hypothetical protein M513_12087 [Trichuris suis] KFD47044.1 +
139_1 hypothetical protein M513_13529 [Trichuris suis] KFD45594.1 c +
139_2 hypothetical protein D918_01462 [Trichuris suis] KHJ48194.1 c
140_1 hypothetical protein M513_10412 [Trichuris suis] KFD48701.1 c
140_2 hypothetical protein M514_10412, partial [Trichuris suis] KFD69291.1 c
141_1 hypothetical protein D918_00022 [Trichuris suis] KHJ48917.1 c
141_2 hypothetical protein M513_07110, partial [Trichuris suis] KFD51978.1 c
141_3 hypothetical protein M514_07110, partial [Trichuris suis] KFD71408.1 c
142_1 hypothetical protein M514_18178 [Trichuris suis] KFD69562.1 + +
142_2 hypothetical protein M513_01929 [Trichuris suis] KFD57044.1 c
143 hypothetical protein M513_11423 [Trichuris suis] KFD47690.1 + +
144 hypothetical protein M513_13284 [Trichuris suis] KFD45838.1 + +
145 hypothetical protein M514_00541 [Trichuris suis] KFD67474.1 +
146 hypothetical protein M514_26563 [Trichuris suis] KFD61265.1 +
147 hypothetical protein M513_00573 [Trichuris suis] KFD58347.1 c +
148 hypothetical protein M513_12471 [Trichuris suis] KFD46662.1 c +
149 hypothetical protein D918_02746 [Trichuris suis] KHJ47180.1 + +
150 hypothetical protein D918_01432 [Trichuris suis] KHJ48165.1 + +
151 hypothetical protein M513_13496 [Trichuris suis] KFD45624.1 + +
152 hypothetical protein M513_11596 [Trichuris suis] KFD47502.1 + +
153 hypothetical protein M514_27849, partial [Trichuris suis] KFD59977.1 + +
154 hypothetical protein M513_12184 [Trichuris suis] KFD46938.1 +
155 hypothetical protein M513_03550 [Trichuris suis] KFD55498.1 + +
156 hypothetical protein M513_14359, partial [Trichuris suis] KFD44764.1 +
157 hypothetical protein M514_27845 [Trichuris suis] KFD59973.1 c +
158 hypothetical protein M513_05101 [Trichuris suis] KFD54082.1 +
159 hypothetical protein M513_06715 [Trichuris suis] KFD52334.1 + +
160 hypothetical protein M513_06707 [Trichuris suis] KFD52326.1 c +
161 hypothetical protein M514_17400 [Trichuris suis] KFD70316.1 c
162 hypothetical protein M513_07352 [Trichuris suis] KFD51825.1 c
163 hypothetical protein M514_11217 [Trichuris suis] KFD67997.1 c
164 hypothetical protein M513_05021 [Trichuris suis] KFD54002.1 c
165 hypothetical protein M513_01675 [Trichuris suis] KFD57572.1 c c
166 hypothetical protein M513_10507 [Trichuris suis] KFD48652.1 c
167 hypothetical protein M514_27025 [Trichuris suis] KFD60805.1 c
168 hypothetical protein M514_24426, partial [Trichuris suis] KFD63405.1 +
169 hypothetical protein M513_13457 [Trichuris suis] KFD45663.1 c
170 hypothetical protein M513_07989 [Trichuris suis] KFD51089.1 c
171 hypothetical protein M513_00299, partial [Trichuris suis] KFD58606.1 c
172 hypothetical protein M513_03825 [Trichuris suis] KFD55184.1 c
173 hypothetical protein M513_01736 [Trichuris suis] KFD57225.1 c
174 hypothetical protein M513_10508 [Trichuris suis] KFD48653.1 c c
175 hypothetical protein M513_05511 [Trichuris suis] KFD53595.1 c
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Supplementary Information S2 
 
S2. Comparison of topology and secondary structure elements of T. suis chitinase with 
mouse chitinases and chitinase like proteins (CLPs). Structure-based amino acid sequence 
alignment of T. suis chitinase (Ts-Chit) with murine Ym1 (Chil3), Ym2 (Chil4), chitotriosidase 
isoforms 1 & 2 (Chit1_1, Chit1_2), AMCase (Chia) and BRP-39 (Chil1). Secondary structure 
elements were predicted and visualized with PSIPRED [1] and SBAL [2], indicating a-helices 
in green, b-strands in red and cysteines in yellow. The top line shows the annotation with 
secondary structure elements observed in the crystal structure of Ts-Chit and the catalytic 
motive DxDxE. 
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